

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number  
**WO 2004/110481 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 39/02**

(74) Agents: **HAGER, Alicia, J. et al.**; Morrison & Foerster  
LLP, 755 Page Mill Road, Palo Alto, CA 94304 (US).

(21) International Application Number:  
**PCT/US2004/003429**

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 6 February 2004 (06.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/446,051 6 February 2003 (06.02.2003) US  
60/449,153 21 February 2003 (21.02.2003) US  
60/490,089 24 July 2003 (24.07.2003) US  
60/511,719 15 October 2003 (15.10.2003) US  
60/511,919 15 October 2003 (15.10.2003) US  
60/511,869 15 October 2003 (15.10.2003) US  
60/541,515 2 February 2004 (02.02.2004) US

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **CERUS CORPORATION** [US/US]; 2411 Stanwell Drive, Concord, CA 94520 (US).

**Published:**

- without international search report and to be republished upon receipt of that report
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DUBENSKY, Thomas, W., Jr.** [US/US]; 15 King Avenue, Piedmont, CA 94511 (US). **BROCKSTEDT, Dirk, G.** [DE/US]; 864 York Street, Apartment 2, Oakland, CA 94610 (US). **COOK, David** [—/US]; 1975 Marion Ct., Lafayette, CA 94549 (US).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **LISTERIA ATTENUATED FOR ENTRY INTO NON-PHAGOCYTIC CELLS, VACCINES COMPRISING THE LISTERIA, AND METHODS OF USE THEREOF**

(57) Abstract: The present invention provides *Listeria* that are attenuated for entry into non-phagocytic cells as well as a variety of methods of inducing immune responses involving administering compositions comprising the attenuated *Listeria*. Some of the attenuated *Listeria* are mutant *Listeria* that comprise at least one mutation in a gene encoding an invasin, such as an internalin. Some of the attenuated *Listeria* are further attenuated for cell-to-cell spread. Pharmaceutical compositions and vaccines useful in the methods of the invention are further provided. Methods of making and improving vaccines are also provided.

WO 2004/110481 A2

**LISTERIA ATTENUATED FOR ENTRY INTO NON-PHAGOCYtic CELLS,  
VACCINES COMPRISING THE LISTERIA, AND METHODS OF USE THEREOF**

**RELATED APPLICATIONS**

[0001] This application claims the priority benefit of U.S. Provisional Application No. 60/446,051, filed February 6, 2003, U.S. Provisional Application No. 60/449,153, filed February 21, 2003, U.S. Provisional Application No. 60/490,089, filed July 24, 2003, U.S. Provisional Application No. 60/511,719, filed October 15, 2003, U.S. Provisional Application No. 60/511,919, filed October 15, 2003, U.S. Provisional Application No. 60/511,869, filed October 15, 2003, and the U.S. Provisional Application entitled "*Listeria* Attenuated for Entry into Non-Phagocytic Cells, Vaccines comprising the *Listeria*, and Methods of Use Thereof," filed February 2, 2004, the contents of each of which are hereby incorporated by reference into the present disclosure.

**FIELD OF THE INVENTION**

[0002] The field of this invention relates generally to attenuated bacteria for use in vaccines. In particular, this invention relates to attenuated *Listeria monocytogenes* useful in vaccine compositions and methods of using those vaccines in treatments.

**BACKGROUND OF THE INVENTION**

[0003] Microbes have been developed for use as vaccines that deliver heterologous antigens. Heterologous antigen delivery is provided by microbes that have been modified to contain nucleic acid sequences encoding a protein or antigen originating from a different species. Heterologous antigen delivery is especially advantageous for treating or preventing diseases or conditions that result from especially virulent or lethal sources, such as cancer and pathogenic agents (for example, HIV or Hepatitis B). Injection of a native or virulent infectious agent is potentially deleterious to the recipient organism. Likewise, a cancer cell which arises sporadically in an affected individual can subsequently propagate and likewise be potentially deleterious to a recipient organism. Heterologous antigen delivery is also especially advantageous where administration of attenuated or killed agent or cell has proven unsuccessful in eliciting an effective immune response or where sufficient attenuation of the infectious agent or cancer cell cannot be assured with acceptable certainty. Recently, certain bacterial strains have been developed as recombinant vaccines. For instance, an oral vaccine

of attenuated *Salmonella* modified to express *Plasmodium berghei* circumsporozoite antigen has been shown to protect mice against malaria (Aggarwal *et al.* 1990. J. Exp. Med. 172:1083).

[0004] One class of bacteria that can potentially be used as heterologous vaccines is facultative intracellular bacteria. The immune response to these bacteria can be a humoral response, a cell-mediated response, or both. However, killed intracellular bacteria or components of intracellular bacteria may not elicit a full cell-mediated immune response (Lauvau *et al.* 2001. *Science* 294:1735-9). These bacteria can spend a portion of their life cycle free in the circulatory or lymphatic systems of their host, where they are subject to the innate and antibody (i.e., humoral) responses of the host's immune system.

[0005] Facultative intracellular bacteria also may spend a portion of their life cycle sequestered within the host's cells, where they may be protected from the innate and humoral aspects of the host's immune system and may be susceptible to the cell-mediated responses of the host's immune system. A cell-mediated immune response is an immune response that stimulates effector T lymphocytes, which may in turn become memory (effector or central) T cells. A cell-mediated immune response results from the presentation of antigens on the surface of host cells. Phagocytic cells of the host's immune system can engulf live bacteria, killed bacteria or components of the bacteria into lysosomes, which mature into phagolysosomes and degrade protein antigens into peptides. Peptides of antigens contained within phagolysosomes of phagocytic cells may be presented on the surface of these phagocytic cells by MHC class II molecules for recognition by CD4+ T cells and the activation of a T helper response. Peptides of antigens expressed in the cytosol of any cell in the body of a mammal may be presented on the surface of that cell by MHC class I molecules for recognition by CD8+ T cells and the activation of a cytotoxic T cell (CTL) response. However, killed intracellular bacteria or components of intracellular bacteria may not invade non-phagocytic cells or may not escape from the phagolysosome of a phagocytic cell into the cytosol, resulting in activation and maturation of phagocytic cells, for example macrophages and dendritic cells. Therefore, the antigens of killed intracellular bacteria or components of intracellular bacteria may not be available for direct MHC I presentation and may not activate a CTL response. The ability of intracellular bacteria to produce proteins within the phagolysosomes and/or cytosol of the host may be necessary in order to elicit a fully effective cell-mediated immune response.

[0006] Strains of *Listeria monocytogenes* have recently been developed as intracellular delivery vehicles of heterologous proteins providing delivery of antigens to the

immune system to induce an immune response to clinical conditions that do not permit injection of the disease-causing agent, such as cancer (U.S. Patent No. 6,051,237 Paterson; U.S. Patent No. 6,565,852) and HIV (US Patent No. 5,830,702, Portnoy & Paterson). As a facultative intracellular bacterium, *L. monocytogenes* elicits both humoral and cell-mediated bacterial antigen-specific immune responses. Following entry of the *Listeria* into a cell of the host organism, the *Listeria* produces *Listeria*-specific proteins that enable it to escape from the phagolysosome of the engulfing host cell into the cytosol of that cell. In the cell, *L. monocytogenes* proliferates, expressing proteins necessary for survival, but also expressing heterologous genes operably linked to *Listeria* promoters. Presentation of peptides of these heterologous proteins on the surface of the engulfing cell by MHC proteins permit the development of a T cell response. Since *L. monocytogenes* is a Gram-positive, food-borne human and animal pathogen responsible for serious infections in immunocompromised individuals and pregnant women, strains of these bacteria must be attenuated in a manner that reduces toxicity to the host, while maintaining immunogenicity of the vaccine. This toxicity is the result of bacterial invasion of various organs and tissues of the host, such as those of the liver, spleen and central nervous system. It would be beneficial to reduce the risks associated with using *Listeria monocytogenes* as a vaccine without affecting its potency to induce adaptive cell-mediated immunity specific for heterologous encoded antigen related to selected infectious and malignant diseases..

#### BRIEF SUMMARY OF THE INVENTION

[0007] The present invention generally provides attenuated *Listeria*, and *Listeria monocytogenes*, in particular, as well as methods of using those *Listeria* in vaccines. The vaccines are useful in the induction of immune responses and in the treatment and/or prevention of a wide array of diseases including cancer.

[0008] In one aspect, the invention provides an isolated *Listeria* bacterium that is attenuated for entry into non-phagocytic cells (e.g., is defective with respect to an internalin, such as internalin B) and which comprises a nucleic acid molecule encoding a non-*Listerial* antigen. In some embodiments, the bacterium is further attenuated for cell-to-cell spread (e.g., is defective with respect to ActA). In some embodiments, the attenuated *Listeria* bacterium belongs to the species *Listeria monocytogenes*. In some embodiments, the attenuated *Listeria* bacterium is a mutant *Listeria* strain. In some embodiments, the *Listeria* bacterium has been attenuated by the binding of antibodies or antibody fragments to the



bacterium. An immunogenic composition comprising the *Listeria* bacterium is also provided, as is a vaccine comprising both the bacterium and a pharmaceutically acceptable carrier and/or an adjuvant. In addition, methods of inducing an immune response in a host to a non-Listerial antigen comprising administering to the host an effective amount of a composition comprising the attenuated *Listeria* bacterium and methods of preventing or treating a disease in a host (such as cancer or an infectious disease), comprising administering to the host an effective amount of a composition comprising the attenuated *Listeria* bacterium are also provided. An isolated professional antigen-presenting cell comprising the attenuated *Listeria* bacterium is also provided.

[0009] In another aspect, the invention provides an isolated *Listeria* bacterium that is attenuated both for entry into non-phagocytic cells (e.g., is defective with respect to an internalin, such as internalin B) and for cell-to-cell spread (e.g., is defective with respect to ActA). In some embodiments, the attenuated *Listeria* bacterium is a mutant *Listeria* strain. In some embodiments, the nucleic acid of the *Listeria* bacterium has been modified with a nucleic acid targeting compound so that the bacterium is attenuated for cell-to-cell spread. In some embodiments, the attenuated *Listeria* bacterium comprises at least one mutation (such as a deletion mutation) in both the *inlB* and *actA* genes. In some embodiments the attenuated *Listeria* is the *Listeria monocytogenes*  $\Delta actA \Delta inlB$  strain (alternatively referred to as the *Listeria monocytogenes* *actA inlB* strain) deposited with the American Type Culture Collection (ATCC) and identified by accession number PTA-5562, or a mutant of the deposited strain which is defective both with respect to internalin B and ActA. In some embodiments the attenuated *Listeria* bacterium comprises a nucleic acid molecule encoding a non-Listerial antigen. In some embodiments, the attenuated *Listeria* bacterium belongs to the species *Listeria monocytogenes*. An immunogenic composition comprising the attenuated *Listeria* is also provided, as is a vaccine comprising both the attenuated *Listeria* and a pharmaceutically acceptable carrier and/or an adjuvant. In addition, methods of inducing an immune response in a host to a non-Listerial antigen comprising administering to the host an effective amount of a composition comprising the attenuated *Listeria* bacterium are provided. Methods of preventing or treating a disease in a host (such as cancer, Listeriosis, or a disease caused by a non-Listerial pathogen), comprising administering to the host an effective amount of a composition comprising the attenuated *Listeria* bacterium are also provided. A professional antigen-presenting cell comprising the attenuated *Listeria* bacterium is further provided.

[0010] In an additional aspect, the invention provides a vaccine comprising (a) a *Listeria* bacterium, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells, and (b) a pharmaceutically acceptable carrier and/or an adjuvant. In some embodiments, the attenuated *Listeria* bacterium is defective with respect to internalin B. In some embodiments, the attenuated *Listeria* bacterium in the vaccine belongs to the species *Listeria monocytogenes*. In some embodiments, the attenuated *Listeria* bacterium is a mutant *Listeria* strain. Methods of inducing an immune response in a host to a non-Listerial antigen comprising administering to the host an effective amount of the vaccine are provided. Methods of preventing or treating a disease in a host, comprising administering to the host an effective amount of the vaccine are also provided.

[0011] In a further aspect, the invention provides an isolated professional antigen-presenting cell comprising a *Listeria* bacterium, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells (e.g., is defective with respect to internalin, such as internalin B). In some embodiments, the bacterium is further attenuated for cell-to-cell spread (e.g., is defective with respect to ActA). In some embodiments, the attenuated *Listeria* bacterium in the professional antigen-presenting cell is a mutant *Listeria* strain. In some embodiments, the *Listeria* bacterium belongs to the species *Listeria monocytogenes*. The invention also provides a method of inducing an immune response in a host to an antigen comprising administering to the host an effective amount of the professional antigen-presenting cell, wherein the attenuated *Listeria* bacterium comprises a nucleic acid encoding an antigen. In still another aspect, the invention provides a method of preventing or treating a disease in a host, comprising administering to the host an effective amount of the professional antigen-presenting cell.

[0012] In another aspect, the invention provides a method of inducing MHC class I antigen presentation or MHC class II antigen presentation on an antigen-presenting cell (*in vivo* or *in vitro*), comprising contacting an attenuated *Listeria* bacterium with an antigen-presenting cell, wherein the attenuated *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-Listerial antigen comprising an MHC class I epitope or an MHC class II epitope.

[0013] In still another aspect, the invention provides a method of inducing an immune response in a host to an antigen, comprising the following steps: (a) contacting an attenuated *Listeria* bacterium with an antigen-presenting cell (e.g., an antigen-presenting cell from the host), wherein the attenuated *Listeria* bacterium is attenuated for entry into non-phagocytic

cells and comprises a nucleic acid molecule encoding the antigen; and (b) administering the antigen-presenting cell to the host.

[0014] In another aspect, the present invention provides a method of preventing or treating disease (such as cancer) in a host, comprising administering to the host a vaccine comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells.

[0015] In another aspect, the invention provides a method of inducing an immune response in a host to an antigen comprising administering to the host an effective amount of a composition comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells, and comprises a nucleic acid molecule encoding the antigen.

[0016] In yet another aspect, the invention provides a method of inducing MHC class I antigen presentation or MHC class II antigen presentation on an antigen-presenting cell comprising contacting a mutant *Listeria* strain with an antigen-presenting cell, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells, and comprises a heterologous nucleic acid molecule encoding an antigen comprising an MHC class I epitope or an MHC class II epitope, respectively.

[0017] In another aspect, the invention provides a method of inducing an immune response in a host to an antigen comprising, the following steps: (a) contacting a mutant *Listeria* strain with an antigen-presenting cell from the host, under suitable conditions and for a time sufficient to load the antigen-presenting cells, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells, and comprises a nucleic acid molecule encoding an antigen; and (b) administering the antigen-presenting cell to the host. In one embodiment, the antigen is a tumor-associated antigen or is derived from a tumor-associated antigen.

[0018] In still another aspect, the invention provides methods for decreasing the pathogenicity of a strain of *Listeria* used in a vaccine, comprising modifying the strain so as to decrease the ability of the strain to enter non-phagocytic cells, but substantially retain the ability of the strain to enter phagocytic cells. These methods may include deletion mutations in genes encoding proteins which direct bacterial tropism (invasins) for particular nonphagocytic cells, or alternatively, may include treatment of bacteria with polyclonal or

monoclonal antibodies which mask said invasins, and as a result inhibit infection of nonphagocytic cells.

[0019] In a further aspect, the invention provides a method of selectively delivering a protein into phagocytic (as opposed to non-phagocytic) cells in a host, comprising administering to the host a composition comprising a mutant *Listeria* strain that is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but substantially retains an ability to enter phagocytic cells, wherein the genome of the mutant *Listeria* strain expressing the protein comprises at least one mutation in at least one gene encoding an invasin (alternatively termed an "invasion protein"), such as an internalin.

[0020] In other aspects, the invention provides methods of making vaccines. For instance, the invention provides a method of making a vaccine comprising contacting a mutant *Listeria* strain with an antigen-presenting cell *in vitro* or *ex vivo*, under suitable conditions and for a time sufficient to load the antigen-presenting cells wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells, and comprises a nucleic acid molecule encoding an antigen.

[0021] In some embodiments of each of the aforementioned aspects, the mutant strain of *Listeria* is a mutant strain of *Listeria monocytogenes* that is defective with respect to internalin B and/or comprises at least one mutation in the gene encoding internalin B (*inlB*), and/or in an element regulating its expression. In still further embodiments of each of the aforementioned aspects, the mutant strain is defective with respect to both internalin B and *actA* and/or comprises at least one mutation in both the *inlB* gene and the *actA* gene, and/or in an element regulating their expression.

[0022] In addition, the present invention provides a variety of compositions and strains useful in the aforementioned methods, as well as other uses. For instance, in a still further aspect, the invention provides a pharmaceutical composition comprising a mutant *Listeria* strain and a pharmaceutically acceptable carrier, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells. In one embodiment, the genome of the mutant strain comprises at least one mutation in at least one gene encoding an invasin (i.e., an invasion protein), such as an internalin, and/or in an element regulating its expression.

[0023] In another aspect, the invention provides an immunogenic composition comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to

enter phagocytic cells, and comprises a heterologous nucleic acid molecule encoding an antigen.

[0024] In another aspect, the invention provides a vaccine comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells.

[0025] In still another aspect, the invention provides a professional antigen-presenting cell, such as a dendritic cell, comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells.

[0026] In some embodiments of each of the aforementioned aspects, the mutant strain of *Listeria* is a mutant strain of *Listeria monocytogenes*.

[0027] In some embodiments of each of the aforementioned aspects, the mutant strain of *Listeria* is defective with respect to internalin B. In some embodiments of each of the aforementioned aspects, the genome of the mutant strain of *Listeria* that is defective with respect to internalin B comprises at least one mutation in the gene encoding internalin B (*inlB*), and/or in an element regulating its expression. In other embodiments, *inlB* is deleted from the genome of the mutant *Listeria* strain.

[0028] In still further embodiments of each of the aforementioned aspects, the mutant strain is defective with respect to both internalin B and ActA. In some embodiments, the mutant strains comprise at least one mutation in both the *inlB* gene (and/or an element regulating expression of the *inlB* gene) and the *actA* gene (and/or in an element regulating expression of the *actA* gene).

[0029] In an additional aspect, the present invention provides a method of preventing or treating disease (such as cancer) in a host, comprising administering to the host a vaccine comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is defective with respect to internalin B.

[0030] In another aspect, the invention provides a method of inducing an immune response in a host to an antigen comprising administering to the host an effective amount of a composition comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is defective with respect to internalin B and comprises a nucleic acid molecule encoding the antigen.

[0031] In another aspect, the invention provides a method of inducing MHC class I antigen presentation or MHC class II antigen presentation on an antigen-presenting cell (*in vitro* or *in vivo*), comprising contacting a mutant *Listeria* strain with an antigen-presenting

cell, wherein the mutant *Listeria* strain is defective with respect to internalin B and comprises a heterologous nucleic acid molecule encoding an antigen comprising an MHC class I epitope or an MHC class II epitope, respectively.

[0032] In still another aspect, the invention provides a method of inducing an immune response in a host to an antigen comprising, the following steps: (a) contacting a mutant *Listeria* strain with an antigen-presenting cell from the host, under suitable conditions and for a time sufficient to load the antigen-presenting cells, wherein the mutant *Listeria* strain is defective with respect to internalin B, and comprises a nucleic acid molecule encoding an antigen; and (b) administering the antigen-presenting cell to the host. In one embodiment, the antigen is a tumor-associated antigen or is derived from a tumor-associated antigen.

[0033] In still another aspect, the invention provides a method of decreasing the pathogenicity of a strain of *Listeria* used in a vaccine, comprising modifying the strain of *Listeria* so that it is defective with respect to internalin B.

[0034] In other aspects, the invention provides methods of making vaccines. For instance, the invention provides a method of making a vaccine comprising contacting a mutant *Listeria* strain with an antigen-presenting cell under suitable conditions and for a time sufficient to load the antigen-presenting cells, wherein the mutant *Listeria* strain is defective with respect to internalin B.

[0035] In addition, the present invention provides a variety of compositions and strains useful in the aforementioned methods, as well as other uses. For instance, in a still further aspect, the invention provides a pharmaceutical composition comprising a mutant *Listeria* strain and a pharmaceutically acceptable carrier, wherein the mutant *Listeria* strain is defective with respect to internalin B. In one embodiment, the genome of the mutant strain comprises at least one mutation in *inlB*, or in an element regulating its expression.

[0036] In another aspect, the invention provides an immunogenic composition comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is defective with respect to internalin B, and comprises a heterologous nucleic acid molecule encoding an antigen.

[0037] In another aspect, the invention provides a vaccine comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is defective with respect to internalin B.

[0038] In still another aspect, the invention provides a professional antigen-presenting cell, such as a dendritic cell, comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is defective with respect to internalin B.

[0039] In some embodiments of each of the aforementioned aspects, the mutant strain of *Listeria* is a mutant strain of *Listeria monocytogenes*.

[0040] In some embodiments of each of the aforementioned aspects, the genome of the mutant strain of *Listeria* that is defective with respect to internalin B comprises at least one mutation in the gene encoding internalin B (*inlB*), and/or in an element regulating its expression. In other embodiments, *inlB* is deleted from the genome of the mutant *Listeria* strain.

[0041] In still further embodiments of each of the aforementioned aspects, the mutant strain is defective with respect to both internalin B and ActA. In some embodiments, the mutant strains comprise at least one mutation in both the *inlB* gene (and/or an element regulating expression of the *inlB* gene) and the *actA* gene (and/or in an element regulating expression of the *actA* gene).

[0042] In an additional aspect, the invention provides a strain of *Listeria monocytogenes* that is defective with respect to both an internalin, such as internalin B, and ActA. In one aspect, the invention provides a strain of *Listeria monocytogenes* that is defective with respect to both internalin B and ActA. In some embodiments, both the *inlB* gene the *actA* gene have been mutated. In one embodiment, both the *inlB* gene and the *actA* gene have been deleted. In one embodiment, the strain is the *Listeria monocytogenes*  $\Delta actA \Delta inlB$  double mutant (alternatively termed a *Listeria monocytogenes* *actA<sup>-</sup>inlB<sup>-</sup>* double mutant) deposited with the American Type Culture Collection (ATCC) on October 3, 2003, and designated with accession number PTA-5562. In another embodiment, the strain is a mutant of the strain designated as PTA-5562, where the mutant is attenuated for entry into non-phagocytic cells relative to wild-type *Listeria monocytogenes*.

[0043] Cultures, immunogenic compositions, and pharmaceutical compositions including vaccines that comprise any of the aforementioned strains are also provided. The use of these particular strains in any and all of the aforementioned methods is also provided.

## DRAWINGS

[0044] Figure 1 shows the target cell populations following injection into mice vaccinated with the indicated *Listeria* strains or vehicle control. Reduced levels of antigen-specific target cells relative to non-specific target cells indicates *in vivo* cytotoxicity of T cells in response to the vaccination. Figure 1A shows *in vivo* cytotoxicity in mice vaccinated IV or IM with the  $\Delta actA$  mutant or the  $\Delta actA \Delta inlB$  double mutant. Figure 1B shows *in vivo* cytotoxicity in mice vaccinated IV with the  $\Delta actA$  mutant or the  $\Delta actA \Delta inlB$  double mutant.

Figure 1C shows *in vivo* cytotoxicity in mice vaccinated IV with the  $\Delta actA \Delta inlB$  double mutant.

[0045] Figure 2 shows the lungs of mice with established CT26 lung tumors given a therapeutic vaccination with mutant *Listeria* strains or a control (Figure 2A). Lung metastases are visible as spots on the lung. The survival of mice from two additional studies is plotted in Figures 2B-C.

[0046] Figure 3 shows the results of IFN- $\gamma$  and TNF- $\alpha$  Intracellular Cytokine Staining (ICS) assays for splenic CD8+ T cells from mice vaccinated with mutant *Listeria*, stimulated with SL8 OVA<sub>257-264</sub> peptide (Figures 3A-B), LLO<sub>190</sub> peptide (Figures 3C-D), or the LLO<sub>296</sub> peptide (Figures 3E-F). ("PCT" indicates data for the S-59/UVA inactivated cells.)

[0047] Figure 4 shows the results of IFN- $\gamma$  ICS assays for spleen cells from mice vaccinated (intravenously) with mutant *Listeria*, stimulated with SL8 OVA<sub>257-264</sub> peptide, live or S-59/UVA inactivated EL-4 cells, or live or S-59/UVA inactivated OVA-expressing EG7 cells.

[0048] Figure 5 shows the results of IFN- $\gamma$  ICS assays for spleen cells from mice vaccinated (intravenously) with varying doses of mutant *Listeria*, stimulated with SL8 OVA<sub>257-264</sub> peptide.

[0049] Figure 6 shows the results of IFN- $\gamma$  ICS assays for spleen cells from mice vaccinated via different routes with mutant *Listeria*, stimulated with SL8 OVA<sub>257-264</sub> peptide.

[0050] Figure 7A and 7B show the accelerated clearance of *Listeria monocytogenes*  $\Delta actA \Delta inlB$  strain *in vivo*. Bacteria levels in the liver over time are shown in the figure.

[0051] Figure 8A and 8B show the accelerated clearance of *Listeria monocytogenes*  $\Delta actA \Delta inlB$  strain *in vivo*. A time course of bacteria levels in the spleen is shown in the figure.

[0052] Figure 9 shows that the *Listeria monocytogenes*  $\Delta inlB$  strain and the *Listeria monocytogenes*  $\Delta actA \Delta inlB$  strain are attenuated for entry into non-phagocytic cells, but not phagocytic cells *in vitro*.

[0053] Figure 10 shows that high titer anti-*Listeria* serum inhibits uptake by non-phagocytic cells, but not by phagocytic cells.

[0054] Figure 11A shows the attenuation of DP-L4029 ( $\Delta actA$ ) *Listeria* strain containing OVA antigen as a function of psoralen S-59 concentration along with the measurement of OVA antigen presentation to a dendritic cell line. The bacterial log titer and % of antigen presentation relative to untreated (linear scale, 1 *Listeria* per DC 2.4 cell) are



plotted vs. nM S-59 (dosed with 0.5 J/cm<sup>2</sup> UVA, washed *Listeria* once, dosed again with 5.5 J/cm<sup>2</sup> UVA).

[0055] Figure 11B shows the attenuation of DP-L4029  $\Delta$ uvrAB *Listeria* strain containing OVA antigen as a function of psoralen S-59 concentration along with the measurement of OVA antigen presentation to a dendritic cell line. The bacterial log titer and % of antigen presentation relative to untreated (linear scale, 1 *Listeria* per DC 2.4 cell) are plotted vs. nM S-59 (dosed with 0.5 J/cm<sup>2</sup> UVA, washed *Listeria* once, dosed again with 5.5 J/cm<sup>2</sup> UVA).

[0056] Figure 11C shows the attenuation of DP-L4029 ( $\Delta$ actA) *Listeria* strain containing OVA antigen as a function of psoralen S-59 concentration along with the measurement of OVA antigen presentation to a dendritic cell line.

[0057] Figure 11D shows the attenuation of DP-L4029  $\Delta$ uvrAB ( $\Delta$ actA $\Delta$ uvrAB) *Listeria* strain containing OVA antigen as a function of psoralen S-59 concentration along with the measurement of OVA antigen presentation to a dendritic cell line.

[0058] Figure 12A shows the induction of OVA specific T cell response in the presence of anti-*Listeria* immunity.

[0059] Figure 12B shows that effective anti-tumor immune response is stimulated in the presence of *Listeria*-specific immunity.

[0060] Figure 12C shows that transfer of *Listeria* immune serum does not prevent priming of OVA-specific CD8+ cells.

## DETAILED DESCRIPTION OF THE INVENTION

### I. Introduction

[0061] The present invention provides *Listeria* that are attenuated for entry into non-phagocytic cells (for instance, mutant strains of *Listeria* that are defective with respect to internalins, such as internalin B.) In some embodiments, the attenuated *Listeria* are further attenuated for cell-to-spread. In some embodiments, the toxicity of the recombinant *Listeria* has been greatly diminished by the modifications made to the strain, and yet, the immunogenicity of the strain has been sufficiently retained. Thus, for the first time, the immunogenicity of the attenuated *Listeria* has been successfully segregated from the toxicity of the *Listeria*. The present invention provides pharmaceutical compositions, immunogenic compositions, and vaccines comprising the attenuated *Listeria*, and the use of these attenuated *Listeria* and *Listeria*-containing compositions to induce immune responses,

including therapeutically effective immune responses in a host. The vaccines and methods can be used either for the prevention of infectious disease caused by *Listeria* or to deliver a heterologous antigen, such as a tumor-associated antigen or an antigen derived from a non-*Listerial* pathogen.

[0062] In particular, the present invention provides attenuated strains of *Listeria monocytogenes* in which the *inlB* gene has been deleted (i.e., a strain attenuated for entry into non-phagocytic cells, for example, hepatocytes via the c-met receptor) or both the *actA* gene and the *inlB* genes have been deleted (i.e., a strain attenuated for both entry into non-phagocytic cells and cell-to-cell spread). The  $\Delta actA \Delta inlB$  strain has been determined to be approximately 1,000-fold less virulent than wild-type *Listeria monocytogenes* (see Example 2 and Table 1, below). The attenuation of the  $\Delta actA \Delta inlB$  *Listeria* strain and the  $\Delta inlB$  *Listeria* strain for entry into non-phagocytic human cells has been confirmed (Example 9, below, and Figure 9). Vaccination with  $\Delta inlB$  and  $\Delta actA \Delta inlB$  *Listeria* strains expressing heterologous antigens has been shown to result in the production of antigen-specific T-cells (see Examples 5-7, below, and Figures 3A, 3B, and 4-6). In addition, vaccination with the  $\Delta actA \Delta inlB$  *Listeria* strain expressing a heterologous antigen has also now been shown to induce an effective robust cytotoxic response to antigen-specific target cells *in vivo* (see Example 3, below, and Figure 1). Furthermore, therapeutic vaccination with the  $\Delta actA \Delta inlB$  *Listeria* strain expressing a heterologous antigen has been shown to be effective in reducing the number of lung metastases and in increasing survival rates in a colorectal cancer mouse model (see Example 4, below, and Figures 2A-C). Additionally, clearance of an  $\Delta actA \Delta inlB$  *Listeria* strain from the liver and spleen has been shown to be much more rapid than that of wild-type *Listeria*, the  $\Delta actA$  *Listeria* strain, or the  $\Delta inlB$  *Listeria* strain (see Example 8, below, and Figures 7-8). That is, the combination of the *actA* and *inlB* deletion mutations together are synergistic, resulting in rapid liver clearance from animals given high IV doses of bacteria.

[0063] Accordingly, the invention provides a *Listeria* bacterium that is attenuated for entry into non-phagocytic cells (e.g., is defective with respect to an internalin, such as internalin B) and which comprises a nucleic acid molecule encoding a non-*Listerial* antigen. In some embodiments, the bacterium is further attenuated for cell-to-cell spread (e.g., is defective with respect to *ActA*). In some embodiments, the attenuated *Listeria* bacterium belongs to the species *Listeria monocytogenes*. In some embodiments, the attenuated *Listeria* bacterium is a mutant *Listeria* strain. An immunogenic composition comprising the *Listeria* bacterium is also provided, as is a vaccine comprising both the bacterium and a

pharmaceutically acceptable carrier and/or an adjuvant. In addition, methods of inducing an immune response in a host to a non-Listerial antigen comprising administering to the host an effective amount of a composition comprising the attenuated *Listeria* bacterium and methods of preventing or treating a disease in a host (such as cancer or an infectious disease), comprising administering to the host an effective amount of a composition comprising the attenuated *Listeria* bacterium are also provided. A professional antigen-presenting cell comprising the attenuated *Listeria* bacterium is also provided.

[0064] The invention also provides a *Listeria* bacterium that is attenuated both for entry into non-phagocytic cells (e.g., is defective with respect to an internalin, such as internalin B) and for cell-to-cell spread (e.g., is defective with respect to ActA). In some embodiments, the attenuated *Listeria* bacterium is a mutant *Listeria* strain. In some embodiments, the attenuated *Listeria* bacterium comprises at least one mutation (such as a deletion mutation) in both the *inlB* and *actA* genes. In some embodiments the attenuated *Listeria* is the *Listeria monocytogenes*  $\Delta actA \Delta inlB$  strain deposited with the American Type Culture Collection (ATCC) and identified by accession number PTA-5562, or a mutant of the deposited strain which is defective both with respect to internalin B and ActA. In some embodiments the attenuated *Listeria* bacterium comprises a nucleic acid molecule encoding a non-Listerial antigen. In some embodiments, the attenuated *Listeria* bacterium belongs to the species *Listeria monocytogenes*. An immunogenic composition comprising the attenuated *Listeria* is also provided, as is a vaccine comprising both the attenuated *Listeria* and a pharmaceutically acceptable carrier and/or an adjuvant. In addition, methods of inducing an immune response in a host to a non-Listerial antigen comprising administering to the host an effective amount of a composition comprising the attenuated *Listeria* bacterium are provided. Methods of preventing or treating a disease in a host (such as cancer, Listeriosis, or a disease caused by a non-Listerial pathogen), comprising administering to the host an effective amount of a composition comprising the attenuated *Listeria* bacterium are also provided. A professional antigen-presenting cell comprising the attenuated *Listeria* bacterium is further provided.

[0065] The invention further provides a vaccine comprising (a) an attenuated *Listeria* bacterium, wherein the attenuated *Listeria* bacterium is attenuated for entry into non-phagocytic cells, and (b) a pharmaceutically acceptable carrier and/or an adjuvant. In some embodiments, the attenuated *Listeria* bacterium is defective with respect to internalin B. In some embodiments, the attenuated *Listeria* bacterium in the vaccine belongs to the species *Listeria monocytogenes*. In some embodiments, the attenuated *Listeria* bacterium is a mutant

*Listeria* strain. Methods of inducing an immune response in a host to a non-*Listerial* antigen comprising administering to the host an effective amount of the vaccine are provided.

Methods of preventing or treating a disease in a host, comprising administering to the host an effective amount of the vaccine are also provided.

[0066] In addition, the invention provides a professional antigen-presenting cell comprising an attenuated *Listeria* bacterium, wherein the attenuated *Listeria* bacterium is attenuated for entry into non-phagocytic cells (e.g., is defective with respect to internalin, such as internalin B). In some embodiments, the bacterium is further attenuated for cell-to-cell spread (e.g., is defective with respect to ActA). In some embodiments, the attenuated *Listeria* bacterium in the professional antigen-presenting cell is a mutant *Listeria* strain. In some embodiments, the *Listeria* bacterium belongs to the species *Listeria monocytogenes*. The invention also provides a method of inducing an immune response in a host to an antigen comprising administering to the host an effective amount of the professional antigen-presenting cell, wherein the attenuated *Listeria* bacterium comprises a nucleic acid encoding an antigen. In still another aspect, the invention provides a method of preventing or treating a disease in a host, comprising administering to the host an effective amount of the professional antigen-presenting cell.

[0067] The invention also provides a method of inducing MHC class I antigen presentation or MHC class II antigen presentation on an antigen-presenting cell (either *in vitro* or *in vivo*), comprising contacting an attenuated *Listeria* bacterium with an antigen-presenting cell, wherein the attenuated *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-*Listerial* antigen comprising an MHC class I epitope or an MHC class II epitope.

[0068] Additionally, the invention provides a method of inducing an immune response in a host to an antigen, comprising the following steps: (a) contacting an attenuated *Listeria* bacterium with an antigen-presenting cell from the host, wherein the attenuated *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding the antigen; and (b) administering the antigen-presenting cell to the host.

[0069] The invention also provides a method of inducing an immune response in a host to an antigen comprising administering to the host an effective amount of a composition comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells, and comprises a nucleic acid molecule encoding the antigen. Within

the host, the antigen is expressed by the mutant *Listeria* in a manner that induces an immune response.

[0070] The present invention provides a method of preventing or treating disease (such as cancer) in a host, comprising administering to the host a vaccine comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells.

[0071] The invention also provides a method of inducing MHC class I antigen presentation or MHC class II antigen presentation on an antigen-presenting cell comprising contacting a mutant *Listeria* strain with an antigen-presenting cell, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells, and comprises a heterologous nucleic acid molecule encoding an antigen comprising an MHC class I epitope or an MHC class II epitope, respectively.

[0072] In addition, the invention provides a method of inducing an immune response in a host to an antigen comprising, the following steps: (a) contacting a mutant *Listeria* strain with an antigen-presenting cell from the host, under suitable conditions and for a time sufficient to load the antigen-presenting cells, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells, and comprises a nucleic acid molecule encoding an antigen; and (b) administering the antigen-presenting cell to the host. In one embodiment, the antigen is a tumor-associated antigen or is derived from a tumor-associated antigen.

[0073] The invention also provides a method of inducing an immune response to an antigen in a host comprising administering to the host an effective amount of a composition comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is defective with respect to internalin B, and comprises a nucleic acid molecule encoding the antigen. Within the host, the antigen is expressed by the mutant *Listeria* in a manner that induces an immune response.

[0074] The present invention also provides a method of preventing or treating disease (such as cancer) in a host, comprising administering to the host a vaccine comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is defective with respect to internalin B.

[0075] The invention further provides a method of inducing MHC class I antigen presentation or MHC class II antigen presentation on an antigen-presenting cell comprising

contacting a mutant *Listeria* strain with an antigen-presenting cell, wherein the mutant *Listeria* strain is defective with respect to internalin B and comprises a heterologous nucleic acid molecule encoding an antigen comprising an MHC class I epitope or an MHC class II epitope, respectively.

[0076] In addition, the invention provides a method of inducing an immune response in a host to an antigen comprising, the following steps: (a) contacting a mutant *Listeria* strain with an antigen-presenting cell from the host, under suitable conditions and for a time sufficient to load the antigen-presenting cells, wherein the mutant *Listeria* strain is defective with respect to internalin B, and comprises a nucleic acid molecule encoding an antigen; and (b) administering the antigen-presenting cell to the host.

[0077] The present invention also provides pharmaceutical compositions, immunogenic compositions, and vaccines comprising a mutant *Listeria* strain that is attenuated for entry into non-phagocytic cells relative to a non-mutant strain, but retains an ability to enter phagocytic cells. In some embodiments, the mutant strains of *Listeria* are defective with respect to one or more invasins, such as internalin B. For instance, in some embodiments, the mutant strain of *Listeria* is a mutant strain of *Listeria monocytogenes* that comprises a mutation in one or more genes encoding an internalin protein (such as internalin B), and/or in an element regulating expression of an internalin protein gene (such as the *inlB* gene). In some embodiments, the strains defective with respect to an internalin protein, such as internalin B, are also defective with respect to a second *Listerial* protein, such as ActA.

[0078] The invention further provides novel strains of *Listeria monocytogenes* that are defective with respect to both internalin B and ActA. For instance, in some embodiments both the *inlB* gene and the *actA* gene have been deleted. In one embodiment, the strain is the *Listeria monocytogenes*  $\Delta actA \Delta inlB$  double mutant deposited with the American Type Culture Collection (ATCC) on October 3, 2003, and designated with accession number PTA-5562.

## II. Attenuated *Listeria*

[0079] The attenuated *Listeria* of the present invention have been developed to permit the expression and delivery of one or more antigens to the phagolysosomes and/or cytosol of professional antigen-presenting cells (APCs), such as macrophages, neutrophils and dendritic cells, while reducing entry of the bacteria into non-APCs, such as the cells of organs and non-immune systems. Accordingly, the *Listeria* bacterium used in the compositions, vaccines,

and methods of the invention is attenuated for entry into non-phagocytic cells, relative to *Listeria* without the relevant attenuating modifications, such as wild type *Listeria*.

[0080] As used herein, the terms "attenuated *Listeria* bacterium" and "modified *Listeria* bacterium" (or "attenuated *Listeria*" and "modified *Listeria*") are used interchangeably herein to refer to a *Listeria* bacterium (or *Listeria*) that is attenuated for entry into non-phagocytic cells relative to wild type *Listeria*. It is understood that the attenuated *Listeria* (i.e., modified *Listeria*) described herein are either non-naturally occurring *Listeria* or *Listeria* that are naturally occurring, but which have now been isolated and/or are now found in a form in which they do not exist in nature. As used herein, the terms "non-attenuated *Listeria* bacterium" and "unmodified *Listeria* bacterium" (or "non-attenuated *Listeria*" and "unmodified *Listeria*") are relative terms used interchangeably herein to refer to *Listeria* bacterium (or *Listeria*) that does not comprise a particular modification that attenuates another *Listeria* bacterium or *Listeria* for entry into non-phagocytic cells relative to wild type *Listeria*. Accordingly, one example of an unmodified *Listeria* is wild type *Listeria*.

[0081] In some embodiments, the attenuated *Listeria* bacterium is a member of a mutant *Listeria* strain, wherein mutations in the genome of the mutant *Listeria* strain render the *Listeria* attenuated for entry into non-phagocytic cells. In some embodiments, the *Listeria* bacterium has been modified through means other than, or in addition to mutation, so that the *Listeria* bacterium is attenuated for entry into non-phagocytic cells (e.g., through antibody binding to the *Listeria*).

[0082] In some embodiments, the attenuated *Listeria* bacterium is not only attenuated for entry into non-phagocytic cells, relative to unmodified *Listeria*, such as wild type *Listeria*, but the attenuated *Listeria* bacterium is also attenuated for cell-to-cell spread, relative to the unmodified *Listeria*. In some embodiments, the attenuated *Listeria* bacterium belongs to a mutant *Listeria* strain that comprises one or more genomic mutations that renders the *Listeria* attenuated for cell-to-cell spread. In some embodiments, the attenuated *Listeria* bacterium has been modified through means other than, or in addition to mutation, so that the *Listeria* bacterium is attenuated for cell-to-cell spread (e.g., through S-59/UVA treatment).

[0083] The attenuated bacteria belong to the genus *Listeria*. In some embodiments, the attenuated *Listeria* belong to a species selected from the group consisting of *Listeria monocytogenes*, *Listeria ivanovii*, *Listeria seeligeri*, or *Listeria innocua*. Furthermore, the invention contemplates the mutation of strains of a variety of *Listeria* species (e.g., a strain that normally expresses internalin B, or its equivalent), especially where those bacteria are

normally pathogenic and/or utilize invasins to invade non-phagocytic eukaryotic cells. In one embodiment, the strain of *Listeria* that is mutated is a pathogenic strain of *Listeria*. In another embodiment, the strain of *Listeria* that is mutated produces at least one invasin. In another embodiment, the strain is *Listeria monocytogenes*, *Listeria ivanovii*, *Listeria seeligeri*, or *Listeria innocua*. In another embodiment, the mutant strain of *Listeria* is a mutant strain of *Listeria monocytogenes*.

[0084] The present invention further provides cultures of the attenuated *Listeria* described herein, such as cultures of the mutant strains.

**A. Attenuation for entry into non-phagocytic cells**

[0085] Generally, the attenuated *Listeria* bacterium of the present invention is a *Listeria* bacterium comprising one or more modifications so that it is attenuated for entry into non-phagocytic cells ("modified *Listeria* bacterium" or "attenuated *Listeria* bacterium") relative to the same *Listeria* bacterium without the modification(s) that render the bacterium attenuated for entry into non-phagocytic cells ("unmodified *Listeria* bacterium" or "non-attenuated *Listeria* bacterium"). A *Listeria* bacterium that is attenuated for entry into non-phagocytic cells is less able to infect at least one type of non-phagocytic cell from the extracellular environment of the non-phagocytic cell than wild type *Listeria* of the same species. In some embodiments, the ability of the attenuated *Listeria* bacterium to enter non-phagocytic cells is reduced by at least about 10%, at least about 25%, at least about 50%, at least about 75%, or at least about 90%, relative to wild type *Listeria*. In some embodiments, the ability of the attenuated *Listeria* bacterium to enter non-phagocytic cells is reduced by at least about 50% relative to wild type *Listeria* of the same species. In other embodiments, the ability of the attenuated *Listeria* bacterium to enter non-phagocytic cells is reduced by at least about 75%.

[0086] In some embodiments, the attenuated *Listeria* bacterium belongs to a mutant *Listeria* strain that comprises one or more mutations in its genome that cause the strain to be attenuated for entry into non-phagocytic cells ("mutant" *Listeria* strain) relative to the same *Listeria* strain without the one or more mutations ("non-mutant" *Listeria* strain). The ability of the attenuated *Listeria* strain to enter non-phagocytic cells may be reduced by at least about 10%, at least about 25%, at least about 50%, at least about 75%, or at least about 90%, relative to the unmodified (non-mutant) *Listeria* strain.

[0087] It is understood that the attenuated *Listeria*, such as a mutant *Listeria* strain, need not necessarily be attenuated for entry into more than one type of non-phagocytic cell.



For instance, the attenuated strain may be attenuated for entry into hepatocytes, but not attenuated for entry into epithelial cells. As another example, the attenuated strain may be attenuated for entry into epithelial cells, but not hepatocytes. It is also understood that attenuation for entry into a non-phagocytic cell of particular modified *Listeria* is a result of mutating a designated gene, for example a deletion mutation, encoding an invasin protein which interacts with a particular cellular receptor, and as a result facilitates infection of a non-phagocytic cell. For example, *Listeria*  $\Delta$ *inlB* mutant strains are attenuated for entry into non-phagocytic cells expressing the hepatocyte growth factor receptor (c-met), including hepatocyte cell lines (e.g., HepG2), and primary human hepatocytes.

[0088] In some embodiments, even though the *Listeria* (e.g., the mutant *Listeria*) are attenuated for entry into non-phagocytic cells, the *Listeria* are still capable of uptake by phagocytic cells, such as at least dendritic cells and/or macrophages. In one embodiment the ability of the attenuated *Listeria* to enter phagocytic cells is not diminished by the modification made to the strain, such as the mutation of an invasin (i.e. approximately 95% or more of the measured ability of the strain to be taken up by phagocytic cells is maintained post-modification). In other embodiments, the ability of the attenuated *Listeria* to enter phagocytic cells is diminished by no more than about 10%, no more than about 25%, no more than about 50%, or no more than about 75%.

[0089] *In vitro* assays for determining whether or not a *Listeria* bacterium (e.g., a mutant *Listeria* strain) is attenuated for entry into non-phagocytic cells are known to those of ordinary skill in the art. For instance, both Dramsi et al., *Molecular Microbiology* 16:251-261 (1995) and Gaillard et al., *Cell* 65:1127-1141 (1991) describe assays for screening the ability of mutant *L. monocytogenes* strains to enter certain cell lines. For instance, to determine whether a *Listeria* bacterium with a particular modification is attenuated for entry into a particular type of non-phagocytic cells, the ability of the attenuated *Listeria* bacterium to enter a particular type of non-phagocytic cell is determined and compared to the ability of the identical *Listeria* bacterium without the modification to enter non-phagocytic cells. Likewise, to determine whether a *Listeria* strain with a particular mutation is attenuated for entry into a particular type of non-phagocytic cells, the ability of the mutant *Listeria* strain to enter a particular type of non-phagocytic cell is determined and compared to the ability of the *Listeria* strain without the mutation to enter non-phagocytic cells.

[0090] In some embodiments of the invention, the amount of attenuation in the ability of the *Listeria* bacterium to enter non-phagocytic cells ranges from a two-fold reduction to

much greater levels of attenuation. In some embodiments, the attenuation in the ability of the *Listeria* to enter non-phagocytic cells is at least about 0.3 log, about 1 log, about 2 log, about 3 log, about 4 log, about 5 log, or at least about 6 log. In some embodiments, the attenuation is in the range of about 0.3 to > 8 log, about 2 to >8 log, about 4 to >8 log, about 6 to >8 log, about 0.3-8 log, also about 0.3-7 log, also about 0.3-6 log, also about 0.3-5 log, also about 0.3-4 log, also about 0.3-3 log, also about 0.3-2 log, also about 0.3-1 log. In some embodiments, the attenuation is in the range of about 1 to >8 log, 1-7 log, 1-6 log, also about 2-6 log, also about 2-5 log, also about 3-5 log.

[0091] In some embodiments, the attenuation of the *Listeria* of the present invention can be measured in terms of biological effects of the *Listeria* on a host. The pathogenicity of a *Listeria* strain can be assessed by measurement of the LD<sub>50</sub> in mice or other vertebrates (Example 2, Table 1). The LD<sub>50</sub> is the amount, or dosage, of *Listeria* injected into vertebrates necessary to cause death in 50% of the vertebrates. The LD<sub>50</sub> values can be compared for *Listeria* having a particular modification (e.g., mutation) versus *Listeria* without the particular modification as a measure of the level of attenuation. For example, if the *Listeria* strain without a particular mutation has an LD<sub>50</sub> of 10<sup>3</sup> bacteria and the *Listeria* strain having the particular mutation has an LD<sub>50</sub> of 10<sup>5</sup> bacteria, the strain has been attenuated so that its LD<sub>50</sub> is increased 100-fold or by 2 log.

[0092] Alternatively, the degree of attenuation of the ability of a *Listeria* bacterium to infect non-phagocytic cells can be assessed much more directly *in vitro*. The ability of a modified *Listeria* bacterium to infect non-phagocytic cells, such as hepatocytes, can be compared to the ability of non-modified *Listeria* or wild type *Listeria* to infect phagocytic cells. In such an assay, the modified and non-modified *Listeria* are typically added to the non-phagocytic cells *in vitro* for a limited period of time (for instance, an hour), the cells are then washed with a gentamicin-containing solution to kill any extracellular bacteria, the cells are lysed and then plated to assess titer. Examples of such an assay are provided in Example 9 and Example 10, below.

[0093] The degree of attenuation may also be measured qualitatively by other biological effects, such as the extent of tissue pathology or serum liver enzyme levels. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin and bilirubin levels in the serum are determined at a clinical laboratory for mice injected with *Listeria* of the present invention. Comparisons of these effects in mice or other vertebrates can be made for *Listeria* with and without particular modifications/mutations as a way to assess the attenuation of the *Listeria*. Attenuation of the *Listeria* relating to the present invention may

also be measured by tissue pathology. The amount of *Listeria* that can be recovered from various tissues of an infected vertebrate, such as the liver, spleen and nervous system, can also be used as a measure of the level of attenuation by comparing these values in vertebrates injected with mutant versus non-mutant *Listeria*. For instance, the amount of *Listeria* that can be recovered from infected tissues such as liver or spleen as a function of time can be used as a measure of attenuation by comparing these values in mice injected with mutant vs. non-mutant *Listeria*.

[0094] Accordingly, the attenuation of the *Listeria* of the present invention can be measured in terms of bacterial load in particular selected organs in mice known to be targets by wild-type *Listeria*. For example, the attenuation of the *Listeria* of the present invention can be measured by enumerating the colonies (Colony Forming Units; CFU) arising from plating dilutions of liver or spleen homogenates (homogenized in H<sub>2</sub>O + 0.2% NP40) on BHI agar media. The liver or spleen cfu can be measured, for example, over a time course following administration of the modified *Listeria* of the present invention via any number of routes, including intravenous, intraperitoneal, intramuscular, and subcutaneous. (See, e.g., Example 8, below.) Additionally, the *Listeria* of the present invention can be measured and compared to a drug-resistant, wild type *Listeria* (or any other selected *Listeria* strain) in the liver and spleen (or any other selected organ) over a over a time course following administration by the competitive index assay, as described.

[0095] The degree of attenuation in uptake of the bacteria involved in the vaccines of the present invention by non-phagocytic cells need not be an absolute attenuation in order to provide a safe and effective vaccine. In some embodiments, the degree of attenuation is one that provides for a reduction in toxicity sufficient to prevent or reduce the symptoms of toxicity to levels that are not life threatening.

**1. *Listeria* comprising mutations that attenuate the *Listeria* for entry into non-phagocytic cells**

[0096] In some embodiments, the attenuated *Listeria* comprise one or more mutations that render the *Listeria* defective with respect to one or more invasins (alternatively termed an invasion protein) normally produced by the *Listeria*, such as an internalin. In some embodiments of the invention, the attenuation in the ability of the attenuated *Listeria* to enter non-phagocytic cells is achieved through the use of mutations that affect one or more invasins expressed by the bacteria. In some embodiments, the attenuated *Listeria* bacterium is a member of a mutant *Listeria* strain that is attenuated for entry into non-phagocytic cells.

[0097] In one embodiment, the attenuated *Listeria* are defective in the production of one or more invasins. An attenuated *Listeria* bacterium is defective with respect to the production of an invasin if the bacterium either produces decreased amounts of a functional version of the invasin or expresses a version of the invasin that is partially or totally nonfunctional, or both. Likewise, a strain of *Listeria* is defective with respect to the production of an invasin if the bacteria of the strain either produce decreased amounts of a functional version of the invasin or express a version of the invasin that is partially or totally nonfunctional, or both.

[0098] In some embodiments, the genome of the attenuated *Listeria* comprises one or more mutations in a gene encoding an invasin, such as an internalin. The mutation is optionally a point mutation, an insertion mutation, a termination mutation, a frame shift mutation, or a deletion of part or whole of the gene encoding the invasin. In some embodiments, the gene encoding the invasin (for example, *inlB*) is deleted.

[0099] In some embodiments, the mutation of the gene encoding the invasin is in the coding sequence. In these embodiments, the mutation of the gene encoding the invasin renders the protein less functional as an invasin than the non-mutated sequence. In some embodiments, the mutation of the gene encoding the invasin renders the protein entirely non-functional.

[0100] In alternative embodiments, expression of at least one gene encoding an invasin in the mutant strain is inhibited relative to a non-mutant strain. For instance, the genome of the mutant *Listeria* may comprise at least one mutation in a gene encoding an invasin, where the mutation hinders expression. For instance, the mutation may be in one or more of the control sequences (such as the promoter or ribosome binding region) of the genes, so that expression of the invasin gene is decreased or eliminated. Alternatively, the mutant *Listeria* may comprise at least one mutation in a gene other than one encoding an invasin, but which nonetheless results in a diminution of the expression levels of one or more invasins.

[0101] Invasins are proteins expressed by *Listeria* that interact with receptors expressed by selected host cells, and as a result, help facilitate penetration of *Listeria* into the host cells. Some invasins are found in the cell wall of *Listeria*. Other invasins are secreted by *Listeria*. Invasins of *Listeria* include, but are not limited to, members of the internalin-related protein family ("internalins"). Internalin proteins typically direct the uptake of *Listeria* by non-phagocytic cells, such as the cells of the liver, spleen or brain.

[0102] A number of internalins have been identified in *L. monocytogenes* (Boland, et al., *Clinical Microbiology Reviews*, 2001, 14: 584-640). These internalins include, but are not limited to, InlA, InlB, InlC, InlC2, InlD, InlE, InlF, InlG, and InlH (Drams, et al., *Infection and Immunity*, 65: 1615-1625 (1997); Raffelsbauer et al., *Mol. Gen. Genet.* 260:144-158 (1988)). The gene sequences encoding these proteins have been previously reported. For instance, the sequences for both *inlA* and *inlB* have been reported in Gaillard et al., *Cell*, 65:1127-1141 (1991) and as GenBank accession number M67471. Genes encoding additional members of the internalin-related protein family are identified in Web Table 2 of the Supplementary Web material of Glaser et al., *Science*, 294:849-852 (2001), ([www.sciencemag.org/cgi/content/full/294/5543/849/DC1](http://www.sciencemag.org/cgi/content/full/294/5543/849/DC1)), including *lmo0327*, *lmo0331*, *lmo0514*, *lmo0610*, *lmo0732*, *lmo1136*, *lmo1289*, *lmo2396*, *lmo0171*, *lmo0333*, *lmo0801*, *lmo1290*, *lmo2026*, and *lmo2821*. (The sequences of each member of the internalin-related protein family can be found in the *L. monocytogenes* strain EGD genome, GenBank Accession no. AL591824, and/or in the *L. monocytogenes* strain EGD-e genome, GenBank Accession no. NC\_003210. Locations of the various internalin-related genes are indicated in Glaser et al.).

[0103] In some embodiments the attenuated *Listeria* bacterium are defective with respect to an internalin such as one or more of the internalin proteins listed above or encoded by an internalin gene listed above. In some embodiments, the attenuated *Listeria* bacterium is defective with respect to internalin B, or its equivalent (depending on the species of *Listeria* used). In other embodiments, the attenuated *Listeria* bacterium is defective with respect to internalin A, or its equivalent (depending on the species of *Listeria* used). In other embodiments, the attenuated *Listeria* bacterium is defective with respect to one or more internalins other than internalin A, or its equivalent (depending on the species of *Listeria* used).

[0104] For instance, the mutant *Listeria* strain is optionally an *L. monocytogenes* strain which has been modified to be defective in the production of functional internalin B. In still another embodiment, the *L. monocytogenes* has been modified to be defective in the production of an internalin other than internalin A (InlA). (It is understood that the proteins that are the functional equivalents of the above-listed internalins, including internalin B, may be present in species of *Listeria* other than *Listeria monocytogenes*. Accordingly, in some embodiments, the mutant *Listeria* strain has been modified to be defective with respect to the production of a protein that is functionally equivalent to internalin B.)

[0105] The mutant *Listeria* strains of the present invention may express less of the wild-type internalin sequence than non-mutant *Listeria* strains. Alternatively, the mutant *Listeria* may express a mutated form of internalin which is non-functional or less functional than that expressed by non-mutant *Listeria*. In still another embodiment, the mutant *Listeria* does not express a particular internalin, such as internalin B, at all because most or all of the gene or sequence encoding the internalin has been deleted.

[0106] In one embodiment the genome of the mutant *Listeria* comprises an attenuating mutation in one or more internalin genes (including, but not necessarily limited to, those listed above). In one embodiment, the genome of the mutant *Listeria* that is attenuated for entry into non-phagocytic cells comprises at least one mutation in a gene selected from the group consisting of the *inlA* gene, *inlB* gene, *inlC* gene, *inlC2* gene, the *inlD* gene, the *inlE* gene, the *inlF* gene, the *inlG* gene, and the *inlH* gene. In another embodiment, the genome of the mutant *Listeria* comprises at least one mutation in a gene selected from the group consisting of the *inlB* gene, *inlC* gene, *inlC2* gene, the *inlD* gene, the *inlE* gene, the *inlF* gene, the *inlG* gene, and the *inlH* gene. In one embodiment, the mutant *Listeria* is a mutant *Listeria monocytogenes* that is defective with respect to internalin B. In still another embodiment, the mutant *Listeria* is a mutant *Listeria monocytogenes* and its genome comprises at least one mutation in the *inlB* gene. In another embodiment the mutant *Listeria* comprises at least one mutation in an internalin gene other than the *inlA* gene. In another embodiment, the mutant *Listeria* comprises at least one mutation in the *inlA* gene.

[0107] Throughout this disclosures (including figures), alternative terminology is used to refer to the genetic mutations, whether they be mutations that attenuate the *Listeria* for entry into non-phagocytic cells or other mutations (such as cell-to-cell spread mutations). The terms “xyz”, “ $\Delta$ xyz”, and “xyz deletion mutant” are used interchangeably herein to refer to deletion mutants in which at least most or all of the xyz gene’s coding sequence. (In many cases, the whole xyz gene has been deleted from these mutants.) For instance, the terms “*inlB*” and “ $\Delta$ *inlB*” and “*inlB* deletion mutant” are generally used interchangeably herein.

[0108] InlA (internalin A) (Gaillard et al., *Cell*, 65:1127-1141 (1991); Genbank accession no. NC\_003210) directs the uptake of *Listeria* by epithelial cells such as those of the intestines. Attenuation of *Listeria* by rendering the strain defective with respect to internalin A may improve the safety of the use of the vaccines in pharmaceutical and vaccine compositions. Invasion of the intestinal epithelial cells by *Listeria* can result in a gastrointestinal infection of *Listeria* characterized by fever, headache, diarrhea or nausea.

[0109] InlB (internalin B) (Gaillard et al., *Cell*, 65:1127-1141 (1991); Genbank accession number AL591975 (*Listeria monocytogenes* strain EGD, complete genome, segment 3/12, *inlB* gene region: nts. 97008-98963); and Genbank accession number NC\_003210 (*Listeria monocytogenes* strain EGD, complete genome, *inlB* gene region: nts. 457008-458963), each of which is incorporated by reference herein in its entirety) directs the uptake of *Listeria* by hepatocytes or by endothelial cells such as the vascular endothelial cells of the brain microvasculature that comprise the blood brain barrier. (For further descriptions of internalin B, see Ireton, et al., *J. of Biological Chemistry*, 274: 17025-17032 (1999); Dramsi, et al., *Molecular Microbiology* 16:251-261 (1995); Mansell et al., *J. of Biological Chemistry*, 276: 43597-43603 (2001); and Bieme et al., *J. of Cell Science* 115:3357-3367 (2002), all of which are incorporated by reference herein in their entirety.) Attenuation of *Listeria* by rendering the strain defective with respect to internalin B may improve the safety of the use of the strains in vaccine and pharmaceutical compositions. Infection of hepatocytes by *Listeria* can result in liver inflammation due to hepatocyte lysis. Infection of brain microvascular endothelial cells can result in meningoencephalitis, which is characterized by headache, stiff neck, loss of balance, confusion, obtundation, convulsions, or death. Meningitis is the leading cause of death by *Listeria* among adults.

[0110] In some embodiments, the mutant *Listeria* strain of the present invention is a strain of *Listeria* that comprises one or more mutations in its genome that cause the strain to be defective with respect to internalin B relative to the *Listeria* strain without the one or more mutations. A strain of *Listeria* is defective with respect to the production of internalin B if the bacteria of the strain either produce decreased amounts of a functional version of internalin B or express a version of internalin B that is partially or totally nonfunctional, or both. (It is understood that the term "internalin B" as used herein refers not only to the internalin B of *Listeria monocytogenes*, but also to equivalents thereof in *Listeria* of other species.)

[0111] In some embodiments, the genome of the *Listeria* comprises one or more mutations in a gene encoding internalin B (*inlB*). The mutation is optionally a point mutation, an insertion mutation, a termination mutation, a frame shift mutation, or a deletion of part or whole of the gene encoding the internalin B. In some embodiments, all or at least the majority of the sequence encoding internalin B is deleted from the genome of the *Listeria*. In some embodiments, most or all of the *inlB* gene is deleted. In some embodiments, no functional internalin B is produced by the attenuated *Listeria*.

[0112] In some embodiments, the mutation of *inlB* is in the coding sequence. In these embodiments, the mutation of the *inlB* renders the internalin B less functional than the protein produced from the non-mutated *inlB* sequence. In some embodiments, the mutation of the *inlB* renders internalin B entirely non-functional (about 100% less functional than the non-mutant *Listeria*). In some embodiments the internalin B expressed by the mutant *Listeria* is at least about 90% less functional, at least about 75% less functional, at least about 50% less functional, or at least about 25% less functional than the internalin B of the non-mutant *Listeria*.

[0113] In alternative embodiments, expression of *inlB* in the mutant strain is inhibited relative to a non-mutant strain. For instance, the genome of the mutant *Listeria* may comprise at least one mutation in *inlB*, where the mutation hinders expression. For instance, the mutation may be in one or more of the control sequences (such as the promoter or ribosome binding region) of *inlB*, so that expression of *inlB* is decreased or eliminated. Alternatively, the mutant *Listeria* may comprise at least one mutation in a gene other than *inlB*, but which nonetheless results in a diminution of the expression levels of internalin B. In some embodiments, expression of internalin B may be reduced by about 100%, by at least about 90%, by at least about 75%, by at least about 50%, or by at least about 25%.

[0114] It should be understood that invasions are bacterial proteins that facilitate infection of non-phagocytic cells, as such can be selected from internalin genes or any other bacterial gene whose encoded product facilitates binding and uptake by non-phagocytic cells.

[0115] Bacterial mutations can be achieved through traditional mutagenic methods, such as mutagenic chemicals or radiation followed by selection of mutants. Bacterial mutations can also be achieved by one of skill in the art through recombinant DNA technology. For instance, a method of allelic exchange is described in Camilli et al., *Molecular Micro.* 8:143-147 (1993) that is suitable for use in generating mutants such as deletions mutants. (Camilli et al., is incorporated by reference herein in its entirety.) (See also Example 1, below, for a description of an exemplary application of allelic exchange.) Alternatively, the gene replacement protocol described in Biswas et al., *J. Bacteriol.* 175:3628-3635 (1993), can be used. Other similar methods are known to those of ordinary skill in the art.

[0116] Confirmation that a particular mutation, such as a particular *inlB* mutation, is present in a strain of *Listeria* and/or that the strain is defective with respect to its production of a particular internalin, such as internalin B, can be obtained through a variety of methods known to those of ordinary skill in the art. For instance, the relevant portion of the strain's



genome can be cloned and sequenced. Alternatively, specific mutations can be identified via PCR using paired primers that code for regions adjacent to a deletion or other mutation. Southern blots can also be used to detect changes in the bacterial genome. Also, one can analyze whether a particular protein is expressed by the strain using techniques standard to the art such as Western blotting. Confirmation that the strain contains a mutation in the desired gene may also be obtained through comparison of the phenotype of the strain with a previously reported phenotype. For instance, confirmation that the strain is defective with respect to internalin B may also be obtained through comparison of the phenotype of the strain with the previously reported phenotypes for internalin B mutants.

[0117] A mutant strain can optionally be evaluated for usefulness in the present invention by evaluating whether or not the strain is attenuated for entry into at least one type of non-phagocytic cell (see Section II.A, above). To determine suitability for use in the methods and compositions of the present invention, the mutant strain can also be evaluated for its ability to be taken up by phagocytic cells.

[0118] The appropriateness of a particular *Listeria* mutant, such as *Listeria* comprising a deletion in a particular internalin gene (e.g., *inlB*), for use in a vaccine can be assessed by measuring the strain's LD<sub>50</sub>, protection afforded by the strain against wild type *Listeria* challenge, ability of the strain to induce specific T cell response to an antigen, ability of the strain to induce an *in vivo* cytotoxic response against cells expressing an antigen, and/or therapeutic effectiveness of the strain *in vivo* against a targeted pathology (e.g. in a mouse model), as well as other types of assays known to those of ordinary skill in the art. Specific examples of some of these assays are shown in the Examples 2-7, below. The measurement of LD<sub>50</sub> of mutant *Listeria* is exemplified in Example 2, below. The immunogenicity of various mutant strains of *Listeria* are tested by ICS assays in Examples 5-7, below. Example 3, below, presents an example of one possible assay for assessing *in vivo* cytotoxicity of mutant *Listeria* strains. Example 4, below, provides an example of an assay testing the therapeutic efficacy of a mutant *Listeria* strain.

[0119] As described above, the invention further provides a method of decreasing the ability of a strain of *Listeria* to enter non-phagocytic cell, while substantially retaining the ability to enter phagocytic cells, comprising introducing at least one mutation into at least one gene of the strain that encodes an invasin so as to decrease the levels of active invasin produced by the strain. In one embodiment, the invasin is an internalin other than *InlA*.

## **2. *Listeria* comprising other modifications that affect entry into non-phagocytic cells**

[0120] In some embodiments, *Listeria* is reacted with polyclonal or monoclonal antibodies (or fragments thereof) that are specific for particular invasin proteins (e.g. internalin B), or, alternatively are specific for multiple antigens or repeated molecular patterns expressed on the surface of the bacterium. Antibodies (Ab) specific for a selected invasin protein or multiple proteins and/or macromolecules cause the *Listeria* to be attenuated for entry into non-phagocytic cells ("Ab-opsonized" *Listeria* strain) relative to the same *Listeria* strain without Ab treatment ("non-opsonized" *Listeria* strain). (See, for instance, Example 10, below.) The ability of the antibody-bound *Listeria* strain to enter non-phagocytic cells may be reduced by at least about 10%, at least about 25%, at least about 50%, at least about 75%, or at least about 90%, relative to the non-antibody-bound *Listeria* strain.

[0121] In some alternative embodiments of the invention, the ability of *Listeria* to enter non-phagocytic cells is attenuated by blockage of one or more key moieties on the surface of the *Listeria*. For instance, a protein involved in the entry of *Listeria* into phagocytic cells may be blocked by an entity which binds the cell-surface protein and blocks its inability to bind to its receptors on a non-phagocytic cell. In some embodiments, an internalin on the surface of the *Listeria* is blocked. In some embodiments, the cell surface protein is internalin B. In some embodiments, the key moiety on the surface of the *Listeria* is blocked with an antibody or an antibody fragment, such as a Fab fragment. In some embodiments, the surface of the *Listeria* is coated with anti-*Listeria* antibodies or antibody fragments.

[0122] In some embodiments, the ability of *Listeria* to enter non-phagocytic cells is effected by opsonization of the *Listeria*. In some embodiments, the attenuated *Listeria* has been opsonized by high titer anti-*Listeria* serum. In some embodiments, the attenuated *Listeria* has been opsonized with polyclonal antibodies. In other embodiments, the attenuated *Listeria* has been opsonized with monoclonal antibodies. In some embodiments, the antibodies used to modify the *Listeria* through opsonization are polyclonal anti-*Listeria* antibodies. In some embodiments, the antibodies used to opsonize the *Listeria* are anti-internalin antibodies, such as internalin B specific monoclonal or polyclonal antibodies, or fragments thereof.

[0123] *Listeria*-specific antibodies can be produced by techniques well-known to those of ordinary skill in the art, such as by i.v. infection of mice with *Listeria* to produce high-titer *Listeria*-specific mouse serum. Opsonized *Listeria* can then be generated by incubation of the *Listeria* to be attenuated with the anti-*Listeria* mouse serum. The inventors

have shown that such resulting opsonized *Listeria* is attenuated for entry into non-phagocytic cells, but not phagocytic cells (see, e.g., Example 10, below).

[0124] Accordingly, in some embodiments, the attenuated *Listeria* bacterium is opsonized. In some embodiments, the opsonized *Listeria* is also attenuated for cell-to-cell spread. For instance, the attenuated *Listeria* bacterium may be an opsonized *Listeria* bacterium that is defective with respect to ActA (e.g., an *actA* deletion mutant).

#### B. Attenuation of *Listeria* for cell-to-cell spread

[0125] In some embodiments, the attenuated *Listeria* used in the compositions, vaccines, and methods described herein are not only attenuated for entry into non-phagocytic cells, but are also attenuated for cell-to-cell spread. A *Listeria* bacterium is attenuated for cell-to-cell spread if the *Listeria* bacterium is less able to spread intercellularly from one infected cell (a cell comprising the *Listeria* within its cytoplasm) to a neighboring cell. In other words, the ability of the attenuated *Listeria* bacterium to grow and spread is diminished relative to wild type *Listeria* of the same species. In some embodiments, the attenuation of the *Listeria* for cell-to-cell spread is directly affected. For instance, in some embodiments, the *Listeria* is attenuated for cell-to-cell spread because the ability of the *Listeria* to form protrusions from the infected cell that enter a neighboring cell is impaired relative to wild type. In other embodiments, the attenuation of the *Listeria* for cell to cell spread is due to a less direct impairment that nonetheless attenuates the *Listeria* for cell-to-cell spread. For instance, in some alternative embodiments, the ability of *Listeria* to exit the vacuole of a phagocytic cell is impaired.

[0126] In some embodiments, the ability of the attenuated *Listeria* to spread cell-to-cell is reduced by at least about 10%, at least about 25%, at least about 50%, at least about 75%, or at least about 90%, relative to wild-type *Listeria*. In some embodiments, the ability of the attenuated *Listeria* to spread cell-to-cell is reduced by at least about 50%, at least about 75%, or at least about 90%, relative to wild-type *Listeria*. In some embodiments, the ability of the attenuated *Listeria* to spread cell-to-cell is reduced by at least about 50% relative to wild type *Listeria*.

[0127] In some embodiments, the attenuated *Listeria* comprise mutations in their genomes which attenuate the *Listeria* for cell-to-cell spread. For instance, in some embodiments, the attenuated *Listeria* bacterium belongs to a mutant strain of *Listeria*. In some embodiments of the present invention, the genome of the mutant strain of *Listeria* comprises one or more mutations in a gene other than an invasin gene. For instance, in some

embodiments, the genome of the mutant strain of *Listeria* comprises one or more mutations in a gene other than *inlB*. For instance, the mutant strain may also be deficient in one or more virulence factors that affect cell-to-cell spread. In other embodiments, the *Listeria* are attenuated for cell-to-cell spread through alternative means.

[0128] Even in those embodiments where the attenuated *Listeria* are attenuated for cell-to-cell spread, the attenuated *Listeria* are preferably still capable of entry into phagocytic cells, such as dendritic cells and/or macrophages. In one embodiment the ability of the attenuated *Listeria* strain to enter phagocytic cells is not diminished by the modification made to the *Listeria* (i.e. approximately 95% or more of the measured ability of the strain to enter phagocytic cells is maintained post-modification). In other embodiments, the ability of the attenuated *Listeria* to enter phagocytic cells is diminished by no more than about 10%, no more than about 25%, no more than about 50%, or no more than about 75%, relative to wild type.

[0129] *In vitro* assays for determining whether or not a *Listeria* bacterium is attenuated for cell-to-cell spread are known to those of ordinary skill in the art. For example, the diameter of plaques formed over a time course after infection of selected cultured cell monolayers can be measured. Plaque assays within L2 cell monolayers can be performed as described previously (Sun, A., A. Camilli, and D.A. Portnoy. 1990, Isolation of *Listeria monocytogenes* small-plaque mutants defective for intracellular growth and cell-to-cell spread. *Infect. Immun.* 58:3770–3778), with modifications to the methods of measurement, as described by (Skoble, J., D.A. Portnoy, and M.D. Welch. 2000, Three regions within ActA promote Arp2/3 complex-mediated actin nucleation and *Listeria monocytogenes* motility. *J. Cell Biol.* 150:527–538). In brief, L2 cells are grown to confluency in six-well tissue culture dishes and then infected with bacteria for 1 h. Following infection, the cells are overlaid with media warmed to 40°C that is comprised of DME containing 0.8% agarose, Fetal Bovine Serum (e.g., 2%), and a desired concentration of Gentamicin. The concentration of Gentamicin in the media dramatically affects plaque size, and is a measure of the ability of a selected *Listeria* strain to effect cell-to-cell spread (Glomski, I J., M. M. Gedde, A. W. Tsang, J. A. Swanson, and D. A. Portnoy. 2002. *J. Cell Biol.* 156:1029–1038). For example, at 3 days following infection of the monolayer the plaque size of *Listeria* strains having a phenotype of defective cell-to-cell spread is reduced by at least 50% as compared to wild-type *Listeria*, when overlaid with media containing Gentamicin at a concentration of 50 µg/ml. On the other hand, the plaque size between *Listeria* strains having a phenotype of

defective cell-to-cell spread and wild-type *Listeria* is similar, when infected monolayers are overlaid with media + agarose containing only 5 µg/ml gentamicin. Thus, the relative ability of a selected strain to effect cell-to-cell spread in an infected cell monolayer relative to wild-type *Listeria* can be determined by varying the concentration of gentamicin in the media containing agarose. Optionally, visualization and measurement of plaque diameter can be facilitated by the addition of media containing Neutral Red (GIBCO BRL; 1:250 dilution in DME + agarose media) to the overlay at 48 h. post infection. Additionally, the plaque assay can be performed in monolayers derived from other primary cells or continuous cells. For example HepG2 cells, a hepatocyte-derived cell line, or primary human hepatocytes can be used to evaluate the ability of selected mutants to effect cell-to-cell spread, as compared to wild-type *Listeria*. In some embodiments, *Listeria* comprising mutations or other modifications that attenuate the *Listeria* for cell-to-cell spread produce "pinpoint" plaques at high concentrations of gentamicin (about 50 µg/ml).

[0130] The attenuation of the attenuated *Listeria* of the present invention can also be measured less directly, in terms of biological effects of the *Listeria* on a host. The pathogenicity of attenuated *Listeria* can be assessed by measurement of the LD<sub>50</sub> in mice or other vertebrates (see Example 2, Table 1). The LD<sub>50</sub> is the amount, or dosage, of *Listeria* injected into vertebrates necessary to cause death in 50% of the vertebrates. The LD<sub>50</sub> values can be compared for *Listeria* having a particular mutation or modification versus *Listeria* without the particular mutation or modification as a measure of the level of attenuation. For example, if the *Listeria* strain without a particular mutation or modification has an LD<sub>50</sub> of 10<sup>3</sup> bacteria and the *Listeria* strain having the particular mutation or modification has an LD<sub>50</sub> of 10<sup>5</sup> bacteria, the strain has been attenuated so that its LD<sub>50</sub> is increased 100-fold or by 2 log.

[0131] The degree of attenuation may also be measured qualitatively by other biological effects, such as the extent of tissue pathology or serum liver enzyme levels. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin and bilirubin levels in the serum are determined at a clinical laboratory for mice injected with *Listeria* of the present invention. Comparisons of these effects in mice or other vertebrates can be made for *Listeria* with and without particular mutations as a way to assess the attenuation of the *Listeria*. Attenuation of the *Listeria* relating to the present invention may also be measured by tissue pathology. The amount of *Listeria* that can be recovered from various tissues of an infected vertebrate, such as the liver, spleen and nervous system, can also be used as a

measure of the level of attenuation by comparing these values in vertebrates injected with attenuated versus non-attenuated *Listeria*. For instance, the amount of *Listeria* that can be recovered from infected tissues such as liver or spleen as a function of time can be used as a measure of attenuation by comparing these values in mice injected with attenuated vs. non-attenuated *Listeria*.

[0132] The degree of attenuation for cell-to-cell spread of the bacteria involved in the vaccines of the present invention need not be an absolute attenuation in order to provide a safe and effective vaccine. In some embodiments, the degree of attenuation is one that provides for a reduction in toxicity sufficient to prevent or reduce the symptoms of toxicity to levels that are not life threatening.

1. *Listeria* comprising mutations that affect cell-to-cell spread

[0133] In some embodiments, the attenuated *Listeria* bacterium comprises one or more mutations that further attenuates the bacterium for cell-to-cell spread. For instance, in some embodiments, the attenuated *Listeria* is a mutant *Listeria* strain that is defective with respect to one or more Listerial protein involved in cell-to-cell spread, such as those selected from the group consisting of ActA, lipote protein ligase, PI-PLC, PC-PLC, zinc-dependent metalloprotease and LLO (or equivalents of these proteins, depending on the species of *Listeria* used). In some embodiments, the attenuated *Listeria* is a mutant *Listeria* strain that comprises one or more mutation in a gene selected from the group consisting of *actA*, *lplA*, *plcA*, *plcB*, *mpl*, and *hly* (or equivalents of these genes, depending on the species of *Listeria* used), wherein the mutation in the gene attenuates the bacterium for cell-to-cell spread.

[0134] In some embodiments, the *Listeria* bacterium is attenuated for entry into non-phagocytic cells (e.g., deficient in one or more internalins such as internalin B) and is also defective with respect to one or more actin polymerizing protein. One such actin polymerizing protein is the actin polymerase encoded by the *actA* gene (Kocks, et al., *Cell*, 68:521-531 (1992); Genbank accession no. AL591974, nt 9456-11389). The actin polymerase protein is involved in the recruitment and polymerization of host F-actin at one pole of the *Listeria* bacterium. Subsequent polymerization and dissolution of actin results in *Listeria* propulsion throughout the cytosol and into neighboring cells. This mobility enables the bacteria to spread directly from cell-to-cell without further exposure to the extracellular environment, thus escaping host defenses such as antibody development. In some embodiments, the attenuated *Listeria* optionally comprises both a mutation in an internalin gene, such as *inlB*, and in *actA*. The *Listeria* strain of this embodiment of the present invention is attenuated for entry into non-phagocytic cells as well as attenuated for cell-to-

cell spreading. The terms "*actA*", " $\Delta actA$ ", and "*actA* deletion mutant" are all used interchangeably herein.

[0135] In some embodiments, the attenuated *Listeria* bacterium is a mutant strain of *Listeria monocytogenes* that is defective with respect to both internalin B and the actin polymerase encoded by *actA*. In another embodiment, the genome of the mutant strain of *Listeria* is a genome of a mutant strain of *Listeria monocytogenes* that comprises a mutation in both *inlB* and *actA* (for example, deletion of most or all of the coding sequences for internalin B and ActA). In one embodiment, the strain is the *Listeria monocytogenes*  $\Delta actA\Delta inlB$  double mutant deposited with the American Type Culture Collection (ATCC) on October 3, 2003, and designated with accession number PTA-5562. In another embodiment, the strain is a mutant of the strain designated as PTA-5562, where the mutant is defective with respect to both internalin B and ActA relative to wild-type *Listeria monocytogenes*. Again, as previously indicated the terms "*actA*" and " $\Delta actA\Delta inlB$ " are used interchangeably herein to refer to the double deletion mutant.

[0136] In some embodiments, the genome of the attenuated *Listeria* is defective for lipoate protein ligase encoded by the *lplA* gene (O'Riordan, et al., *Science*, 302:462-4 (2003); Genbank accession no. NC\_003210). In some embodiments, the attenuated *Listeria* is defective both with respect to internalin B and a lipoate protein ligase. In some embodiments, the attenuated *Listeria* is a mutant that comprises a mutation in the *lplA* gene. In some embodiments, the attenuated *Listeria* comprises a mutation in both *inlB* and *lplA*. Some exemplary *lplA* mutants are described in the published U.S. application 2004/0013690, incorporated by reference herein in its entirety.

[0137] In some embodiments, the *Listeria* bacterium that is attenuated for entry into non-phagocytic cells is also defective with respect to one or more phospholipases. In some embodiments, the attenuated *Listeria* is a mutant *Listeria* strain defective with respect to one or more internalins (such as internalin B) and also defective with respect to and/or mutated in one or more phospholipases. Phospholipases are a class of enzymes that catalyze the hydrolysis of phosphoglycerides. Phospholipase C is a phosphodiesterase that releases diacyl glycerol, a second messenger in other bacterial pathways. In *Listeria* these contribute to the formation of pores in the phagolysosomal membrane. In some embodiments, the phospholipase genes that are mutated in the *Listeria* involved in the present invention are selected from the group consisting of *plcA*, *plcB* and *smcL*. In some embodiments, the attenuated *Listeria* is defective with respect to PC-PLC and/or PI-PLC. In some embodiments, the attenuated *Listeria* comprises one or more mutations in the *plcA* and/or

*plcB* genes (Genbank accession no. NC\_003210; Angelakopoulos H. et al., 2002, Infect. Immun. 70:3592-3601). In some embodiments, the attenuated *Listeria* comprises a mutation in the *smcL* gene. In some embodiments, the attenuated *Listeria* comprises attenuating mutations in *inlB* and in *plcA* and/or *plcB*. The *Listeria* strain of these embodiments of the present invention is attenuated for entry into non-phagocytic cells as well as escape from the phagolysosome into the cytosol of the host cell, and, as a result, for cell-to-cell spread.

[0138] In some embodiments, the genome of the attenuated *Listeria* is defective for the zinc-dependent metalloprotease encoded by the *mpl* gene (Marquis, et al., *J. Cell. Biol.* 137:1381-92 (1997); Genbank accession no. NC\_003210). In some embodiments, the attenuated *Listeria* is defective both with respect to internalin B and a zinc-dependent metalloprotease. In some embodiments, the attenuated *Listeria* is a mutant that comprises a mutation in the *mpl* gene. In some embodiments, the attenuated *Listeria* comprises an attenuating mutation in both *inlB* and *mpl*.

[0139] In some embodiments, the *Listeria* bacterium that is attenuated for entry into non-phagocytic cells is also defective with respect to LLO. In some embodiments, the mutant strains of *Listeria* that are defective with respect to one or more invasins (e.g., internalin B) are also defective with respect to and/or mutated for one or more *Listeria* proteins effective in mediating the escape and spread of *Listeria* from the initial site of invasion. Such escape proteins can comprise native listeriolysin O (LLO; Genbank accession no. M24199, incorporated herein by reference in its entirety) as well as mutant forms of LLO. In some embodiments, the genome of the attenuated *Listeria* bacterium comprises a mutation in the *hly* gene that encodes LLO. LLO is a cytolysin protein responsible for forming pores in the membrane of the phagolysosomes that encapsulate invading *Listeria*. These pores enable *Listeria* to escape the killing environment of the phagolysosome into the cytosol of the host cell, where the *Listeria* can grow and spread to neighboring cells. One possible mutant LLO protein of the *Listeria* comprises amino acid substitutions. Such amino acid substitutions can involve one or more amino acids of the LLO protein and can affect the cytotoxicity of the LLO by altering the pH optimum or the stability of the resulting protein. Another mutant LLO protein of the *Listeria* involved in the present invention comprises the deletion of one or more amino acids of the LLO. Such amino acid deletions can also affect the cytotoxicity by altering the stability of the resulting LLO protein. The *Listeria* strains involved in the present invention that are deficient in one or more internalins and are also deficient or mutated for the LLO protein are attenuated for entry into non-phagocytic cells as well as attenuated for escape from the phagolysosome and the resulting growth and spread



directly from cell to cell. Some exemplary *hly* mutants are described in the published U.S. application 2004/0013690, incorporated by reference herein in its entirety.

[0140] Accordingly, in some embodiments, the genome of the *Listeria* bacterium attenuated for entry into non-phagocytic cells is further attenuated for cell-to-cell spread and comprises at least one mutation in one or more genes selected from the group consisting of *actA*, *hly*, *lplA*, *plcA*, *mpl* and *plcB*. In an alternative embodiment, the genome of the mutant strain further comprises at least one mutation in *actA*. For example, the genome of the modified *Listeria* bacterium may comprise at least one mutation in both *inlB* and a gene selected from the group consisting of *actA*, *hly*, *lplA*, *plcA*, *mpl* and *plcB*. Alternatively, the genome of the attenuated *Listeria* comprises at least one mutation in both *inlB* and *actA*.

[0141] The additional mutations in the *Listeria* strains can be introduced and screened for in the same manner as that described in Section II.A, above, or in the Examples, below. Multiple mutations will typically be introduced sequentially. For instance, starting with wild-type *Listeria*, the *actA* gene can be deleted using allelic exchange. Lastly, the *inlB* gene can then be deleted from the *actA* mutant or the *actA/uvrAB* mutant through allelic exchange to generate the *actA/inlB* mutant.

[0142] In alternative embodiments, existing mutant *Listeria* strains known to those in the art are further modified to introduce mutations that will attenuate their ability to enter non-phagocytic cells and/or to render the strains defective with respect to internalin B. For instance, a number of mutant *Listeria* strains, have been described previously. The mutant strain LLO L461T (DP-L4017) was described in Glomski, et al, *J. Cell. Biol.* 156: 1029 (2002), incorporated by reference herein. The  $\Delta actA$  mutant (DP-L4029) is the DP-L3078 strain described in Skoble et al., *J. of Cell Biology*, 150: 527-537 (2000), incorporated by reference herein in its entirety, which has been cured of its prophage. (Prophage curing is described in (Lauer et al., *J. Bacteriol.* 184:4177 (2002); U.S. Patent Publication No. 2003/0203472).) The LLO mutant (DP-L4027) (Lauer et al., *J. of Bacteriology*, 184:4177-4186 (2002)), and LLO  $\Delta 26$  (DP-L4042) (Decatur et al, *Science* 290:992 (2000)) were also described previously. Any of these strains could comprise a starting point to produce a mutant *Listeria* strain of the present invention. Alternatively, any one of a wide variety of mutant *Listeria* strains may first be generated from wild-type *Listeria* using the allelic exchange methods described above or other methods known to those of ordinary skill in the art and then the mutation attenuating the bacteria for entry into non-phagocytic cells (such as *inlB*) may be introduced into the strain at a later point.

[0143] The appropriateness of a particular *Listeria* strain attenuated for entry into non-phagocytic cells (e.g., a strain defective with respect to internalin B) that is also attenuated for cell-to-cell spread for use in a vaccine can be assessed using the same types of assays as described for assessing proper mutations affecting invasins in Section II.A., above.

[0144] It is understood that the genomes of the attenuated *Listeria* of the present invention may also comprise additional mutations that neither attenuate the *Listeria* for entry into non-phagocytic cells nor for cell-to-cell spread.

## 2. *Listeria* comprising other modifications that affect cell-to-cell spread

[0145] In some embodiments, the *Listeria* bacterium that is attenuated for both entry into non-phagocytic cells and for cell-to-cell spread has been modified by alternative means (or by a means in addition to) those mutations outlined above. For instance, in some embodiments, the *Listerial* nucleic acid of the *Listeria* bacterium has been modified so that proliferation of the bacterium is attenuated, thereby attenuating the bacterium for cell-to-cell spread.

[0146] In some embodiments, the attenuation of the proliferation of the *Listeria* is controllable in a dose-dependent manner. In some embodiments, the expression of *Listerial* genes in the *Listeria* bacterium is substantially unaffected by attenuation of the proliferation of the microbe. In some embodiments, the *Listeria* expresses an antigen at a sufficient level to induce an immune response to the antigen in an individual upon administration of the vaccine to the individual.

[0147] In some embodiments, the nucleic acid of the bacterium has been modified by reaction with a nucleic acid targeting compound so that proliferation of the bacterium is attenuated. In some embodiments, the nucleic acid of the *Listeria* has been modified by reaction with a nucleic-acid targeting compound that reacts directly with the nucleic acid. In some embodiments, the nucleic-acid targeting compound is a nucleic acid alkylator. For instance, in some embodiments, the nucleic acid alkylator is  $\beta$ -alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester. In some embodiments, the nucleic acid targeting compound is activated by irradiation. In some embodiments, the nucleic acid targeted compound is a psoralen compound activated by UVA irradiation and the nucleic acid of the attenuated *Listeria* bacterium has been modified by contact with the psoralen compound activated by UVA irradiation. For instance, in some embodiments, the nucleic acid targeting compound is 4'-(4-amino-2-oxa)butyl-4,5',8-trimethylpsoralen (also referred to herein as "S-59"). Exemplary protocol for S-59/UVA inactivation of *Listeria* are provided in Example 11, below. Further descriptions of the use of targeting compounds such as crosslinking

compounds are provided in the related applications U.S. Serial Nos. 60/446,051, 60/449,153, and 60/511,869, incorporated by reference herein in their entirety. Likewise, the related U.S. patent application entitled "Modified Free-Living Microbes, Vaccine Compositions, and Methods of Use Thereof," filed on February 6, 2004, is also incorporated by reference herein in its entirety.

[0148] In some embodiments, the attenuated *Listeria* bacterium has not only been attenuated for entry into non-phagocytic cells and its nucleic acid modified so that it is attenuated for proliferation (as described above), but it is also defective with respect to a protein that functions to repair modifications to the Listerial nucleic acid. In some embodiments, the attenuated *Listeria* is defective with respect to a DNA repair enzyme. In some embodiments, the mutant *Listeria* strain is deficient with respect to both internalin B and a protein that functions to repair modifications to its nucleic acid. For instance, a mutant strain of *Listeria* that comprises a mutation in *inlB* could also comprise a mutation in any of a variety of genes that are involved in the DNA repair mechanisms of microbes (Aravind et al., *Nucleic Acids Research* 27(5):1223-1242 (1999)). In one embodiment the repair deficient mutant lacks the ability to make PhrB (a photolyase), which repairs pyrimidine dimers. For example, the additional mutation may be in the *phrB* gene, or a functionally equivalent gene, depending on the species of the *Listeria*. Such a mutant could be used in conjunction with ultraviolet irradiation (e.g., UVB, UVC) of the microbe to produce pyrimidine dimers in the microbial nucleic acid. In another embodiment the internalin B mutant is also unable to repair interstand crosslinks. Such mutants include, but are not limited to, mutations in one or all *uvr* genes, i.e. *uvrA*, *uvrB*, *uvrC*, and *uvrD* genes as well as *recA* genes, or functionally equivalent genes, depending on the genus and species of the microbe. These mutations result in attenuation in the activity of the corresponding enzymes UvrA (an ATPase), UvrB (a helicase), UvrC (a nuclease), UvrD (a helicase II) and RecA (a recombinase). These mutants would typically be used in conjunction with a crosslinking compound, such as a psoralen. In one embodiment, there are attenuating mutations in both *uvrA* and *uvrB* (*uvrAB*).

[0149] Accordingly, in one embodiment, the genome of the mutant strain attenuated for entry into non-phagocytic cells, further comprises at least one mutation in a least one gene selected from the group consisting of *phrB*, *uvrA*, *uvrB*, *uvrC*, *uvrD*, and *recA*. For example, the genome of the mutant *Listeria* may comprise at least one mutation in both *inlB* and a gene selected from the group consisting of *phrB*, *uvrA*, *uvrB*, *uvrC*, *uvrD*, and *recA*. Alternatively, the attenuated *Listeria* is a mutant *Listeria monocytogenes* that comprises at least one mutation in *inlB*, *actA*, and *uvrAB*.

[0150] The additional mutations in the *Listeria* strains can be introduced and screened for in the same manner as that described in Section II.A, above, or in the Examples, below. Multiple mutations will typically be introduced sequentially. For instance, starting with wild-type *Listeria*, the *actA* gene can be deleted using allelic exchange. Next, the *uvrA* and *uvrB* genes can optionally be deleted from the  $\Delta actA$  mutant using allelic exchange. (A *Listeria monocytogenes*  $\Delta actA \Delta uvrAB$  mutant was deposited with ATCC on October 3, 2003, and designated PTA-5563.) Lastly, the *inlB* gene can then be deleted from the  $\Delta actA$  mutant or the  $\Delta actA \Delta uvrAB$  mutant (also known as *actA<sup>-</sup>/uvrAB<sup>-</sup>*) through allelic exchange to generate the  $\Delta actA \Delta inlB \Delta uvrAB$  (also known as *actA<sup>-</sup>/inlB<sup>-</sup>/uvrAB<sup>-</sup>*) mutant.

[0151] In alternative embodiments, existing mutant *Listeria* strains known to those in the art are further modified to introduce mutations that will attenuate their ability to enter non-phagocytic cells and/or to render the strains defective with respect to internalin B. For instance, construction of the  $\Delta actA \Delta uvrAB$  strain is described in the copending U.S. provisional application 60/446,051, filed February 6, 2003, as L4029/*uvrAB* (see, e.g. Example 7 of that application). This strain could comprise a starting point to produce a mutant *Listeria* strain of the present invention. Alternatively, any one of a wide variety mutant *Listeria* strains may first be generated from wild-type *Listeria* using the allelic exchange methods described above or other methods known to those of ordinary skill in the art and then the mutation attenuating the bacteria for entry into non-phagocytic cells (such as *inlB*) may be introduced into the strain at a later point.

[0152] The appropriateness of a particular attenuated *Listeria* strain (e.g., a strain defective with respect to internalin B) that is also attenuated for cell-to-cell spread for use in a vaccine can be assessed using the same types of assays as described for assessing proper mutations affecting invasins in Section II.A., above.

[0153] U.S. Provisional application nos. 60/446,051, 60/449,153, and 60/511,869 (each of which is incorporated by reference) provide additional information regarding the preparation and assessment of attenuated *Listeria* comprising genetic mutations that attenuate the ability of the *Listeria* to repair its nucleic acid that has been modified. Likewise, the related U.S. patent application entitled "Modified Free Living Microbes, Vaccine Compositions, and Methods of Use Thereof," filed on February 6, 2004, is also incorporated by reference herein in its entirety.

### C. Antigens and heterologous protein expression

[0154] In some embodiments of the present invention, the attenuated *Listeria* (e.g., the mutant *Listeria* strains) comprise a nucleic acid molecule encoding an antigen. In some embodiments, the antigen is a Listerial antigen. Alternatively, the antigen is a non-*Listerial* antigen. In some, although not all, embodiments of the invention, the nucleic acid encoding the antigen is heterologous with respect to the mutant *Listeria*. The nucleic acid molecule encoding the antigen may be integrated into the genome of the mutant *Listeria*. Alternatively, the nucleic acid molecule encoding the antigen may be on a plasmid or the like within the *Listeria*.

[0155] The antigen that is expressed by the heterologous nucleic acid in the mutant *Listeria* strain may be either autologous or heterologous to a host animal to which the mutant *Listeria* strain is administered as part of a vaccine or other composition.

[0156] Methods of preparing *Listeria* containing heterologous nucleic acids that express antigens are known to those of ordinary skill in the art. The *Listeria* may be altered by recombinant DNA methods known to those skilled in the art (see, e.g., Sambrook and Russell, *Molecular Cloning: A Laboratory Manual*, Third Edition, Cold Spring Harbor Laboratory Press, (2000)). The coding sequence for the antigen, or a fragment and/or variant thereof, is operably linked to appropriate regulatory sequences to effect expression of the antigen sequence within the *Listeria*. Suitable promoter sequences are known to those of ordinary skill in the art. For instance, the *hly* promoter is suitable for use in the expression constructs. In some embodiments, the expression constructs containing the antigen coding sequences further comprise operably linked signal peptide sequences. In some embodiments, the antigen sequence is fused, directly or indirectly, to sequences encoding at least portions of *Listerial* proteins such as LLO. Specific examples of integrational vectors suitable for expression of antigens in *Listeria* include pPL2 and pPL1, described in Lauer et al., *J. Bacteriol.* 184:41777-4186 (2002) and U.S. Patent Pub. No. 2003/0203472 A1, incorporated by reference herein in their entirety.

[0157] The heterologous nucleic acid sequence can encode at least one specific protein antigen or other protein, such as a protein that provides a palliative treatment for a disease. The *Listeria* can be altered to contain one or more sequences that encode one or more antigens or other desired proteins. The heterologous nucleic acid sequence encoding a specific antigen is not limited to an exact nucleic acid sequence but is of a sequence that is sufficient to provide the expression of an antigen that will elicit the desired immune response when administered to an individual. Similarly for heterologous sequences encoding other proteins, the sequences encoding a given protein may vary so long as the desired protein is

expressed in order to provide the desired effect (e.g. a palliative effect) when administered to an individual. The heterologous sequence can be expressed as an antigen related to a particular disease. The *Listeria* expressing such antigens can be used as a vaccine, wherein the vaccine may be used as a preventative treatment or a therapeutic treatment. Diseases that can be treated by such vaccines include, but are not limited to, infectious diseases, autoimmune diseases, allergies, cancers and other hyperproliferative diseases.

[0158] The *Listeria* involved in the invention may be altered to contain a heterologous nucleic acid sequence encoding an antigen that is a tumor-associated antigen or is derived from a tumor-associated antigen. A large number of tumor-associated antigens that are recognized by T cells have been identified (Renkvist et al., *Cancer Immunol Innumother* 50:3-15 (2001)). These tumor-associated antigens may be differentiation antigens (e.g., PSMA, Tyrosinase, gp100), tissue-specific antigens (e.g. PAP, PSA), developmental antigens, tumor-associated viral antigens (e.g. HPV 16 E7), cancer-testis antigens (e.g. MAGE, BAGE, NY-ESO-1), embryonic antigens (e.g. CEA, alpha-fetoprotein), oncoprotein antigens (e.g. Ras, p53), over-expressed protein antigens (e.g. ErbB2 (Her2/Neu), MUC1), or mutated protein antigens. The tumor-associated antigens that may be encoded by the heterologous nucleic acid sequence include, but are not limited to, 707-AP, Annexin II, AFP, ART-4, BAGE,  $\beta$ -catenin/m, BCL-2, bcr-abl, bcr-abl p190, bcr-abl p210, BRCA-1, BRCA-2, CAMEL, CAP-1, CASP-8, CDC27/m, CDK-4/m, CEA (Huang et al., *Exper Rev. Vaccines* (2002)1:49-63), CT9, CT10, Cyp-B, Dek-cain, DAM-6 (MAGE-B2), DAM-10 (MAGE-B1), EphA2 (Zantek et al., *Cell Growth Differ.* (1999) 10:629-38; Carles-Kinch et al., *Cancer Res.* (2002) 62:2840-7), ELF2M, ETV6-AML1, G250, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, GnT-V, gp100, HAGE, HER2/neu, HLA-A\*0201-R170I, HPV-E7, HSP70-2M, HST-2, hTERT, hTERT, iCE, inhibitors of apoptosis (e.g. survivin), KIAA0205, K-ras, LAGE, LAGE-1, LDLR/FUT, MAGE-1, MAGE-2, MAGE-3, MAGE-6, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MAGE-B5, MAGE-B6, MAGE-C2, MAGE-C3, MAGE-D, MART-1, MART-1/Melan-A, MC1R, MDM-2, mesothelin, Myosin/m, MUC1, MUC2, MUM-1, MUM-2, MUM-3, neo-polyA polymerase, NA88-A, NY-ESO-1, NY-ESO-1a (CAG-3), PAGE-4, PAP, Proteinase 3 (Molldrem et al., *Blood* (1996) 88:2450-7; Molldrem et al., *Blood* (1997) 90:2529-34), P15, p190, Pm1/RAR $\alpha$ , PRAME, PSA, PSM, PSMA, RAGE, RAS, RCAS1, RU1, RU2, SAGE, SART-1, SART-2, SART-3, SP17, SPAS-1, TEL/AML1, TPI/m, Tyrosinase, TARP, TRP-1 (gp75), TRP-2, TRP-2/INT2, WT-1, and alternatively translated

NY-ESO-ORF2 and CAMEL proteins, derived from the NY-ESO-1 and LAGE-1 genes. The attenuated *Listeria* of the present invention may encompass any tumor-associated antigen that can elicit a tumor-specific immune response, including antigens yet to be identified. The *Listeria* may be altered to contain more than one heterologous sequence encoding more than one tumor-associated antigen. In one embodiment, the antigen is mesothelin (Argani et al., *Clin Cancer Res.* 7(12):3862-8 (2001)), Sp17 (Lim et al., *Blood* 97(5):1508-10 (2001)), gp100 (Kawakami et al., *Proc. Natl. Acad. Sci. USA* 91:6458 (1994)), PAGE-4 (Brinkmann et al., *Cancer Res.* 59(7):1445-8 (1999)), TARP (Wolfgang et al., *Proc. Natl. Acad. Sci. USA* 97(17):9437-42 (2000)), or SPAS-1 (U.S. Patent Application Publication No. 2002/0150588).

[0159] In some embodiments, the heterologous nucleic acid encodes an antigen that is not identical to a tumor-associated antigen, but rather is derived from a tumor-associated antigen. For instance, the antigen expressed by the mutant *Listeria* may comprise a fragment of a tumor-associated antigen, a variant of a tumor-associated antigen, or a fragment of a variant of a tumor-associated antigen. In some cases, an antigen, such as a tumor antigen, is capable of inducing a more significant immune response in a vaccine when the sequence differs from that endogenous to the host. In some embodiments, the variant of a tumor-associated antigen, or a fragment of a variant of a tumor-associated antigen, differs from that of the tumor-associated antigen, or its corresponding fragment, by one or more amino acids. The antigen derived from a tumor-associated antigen will comprise at least one epitope sequence capable of inducing the desired immune response upon administration of the mutant *Listeria* to a host.

[0160] Accordingly, in some embodiments, the attenuated *Listeria* bacterium comprises a nucleic acid molecule encoding an antigen such as mesothelin, SPAS-1, proteinase-3, EphA2, SP-17, gp100, PAGE-4, TARP, Her-2/neu, WT-1, NY-ESO-1, PSMA, K-ras, or CEA, or an antigen derived from one of those proteins. In some embodiments, the attenuated *Listeria* bacterium comprises a nucleic acid molecule encoding an antigen such as mesothelin, SPAS-1, proteinase-3, SP-17, gp100, PAGE-4, TARP, Her-2/neu, WT-1, NY-ESO-1, PSMA, K-ras, or CEA, or an antigen derived from one of those proteins. In some embodiments, the attenuated *Listeria* bacterium comprises a nucleic acid molecule encoding an antigen such as mesothelin, SPAS-1, proteinase-3, EphA2, SP-17, gp100, PAGE-4, TARP, WT-1, NY-ESO-1, or CEA, or an antigen derived from one of those proteins. In other embodiments, the attenuated *Listeria* bacterium comprises a nucleic acid molecule encoding an antigen such as mesothelin, SPAS-1, proteinase-3, SP-17, gp100, PAGE-4, TARP, WT-1, NY-ESO-1, or CEA, or an antigen derived from one of those proteins. In

some embodiments, the attenuated *Listeria* bacterium comprises a nucleic acid molecule encoding human mesothelin, or an antigen derived from human mesothelin. In other embodiments, the attenuated *Listeria* bacterium comprises a nucleic acid molecule encoding human EphA2, or derived from human EphA2. In further embodiments, the attenuated *Listeria* bacterium comprises a nucleic acid molecule encoding human NY-ESO-1, or an antigen derived from human NY-ESO-1.

[0161] In some other embodiments, the heterologous antigen expressed by the attenuated *Listeria* is proteinase-3 or is derived from proteinase-3. For instance, in one embodiment, the antigen comprises the HLA-A2.1-restricted peptide PR1 (aa 169-177; VLQELNVTV (SEQ ID NO:1)). Information on proteinase-3 and/or the PR1 epitope is publicly available in the following references: US Patent No. 5,180,819, Molldrem, et al., *Blood*, 90:2529-2534 (1997); Molldrem et al., *Cancer Research*, 59:2675-2681 (1999); Molldrem, et al., *Nature Medicine*, 6:1018-1023 (2000); and Molldrem et al., *Oncogene*, 21: 8668-8673 (2002).

[0162] Alternatively, the attenuated *Listeria* of the invention may be altered to contain a heterologous nucleic acid sequence encoding an autoimmune disease-specific antigen. In a T cell mediated autoimmune disease, a T cell response to self antigens results in the autoimmune disease. The type of antigen for use in treating an autoimmune disease with the vaccines of the present invention might target the specific T cells responsible for the autoimmune response. For example, the antigen may be part of a T cell receptor, the idiotype, specific to those T cells causing an autoimmune response, wherein the antigen incorporated into a vaccine of the invention would elicit an immune response specific to those T cells causing the autoimmune response. Eliminating those T cells would be the therapeutic mechanism to alleviating the autoimmune disease. Another possibility would be to incorporate an antigen that will result in an immune response targeting the antibodies that are generated to self antigens in an autoimmune disease or targeting the specific B cell clones that secrete the antibodies. For example, an idiotype antigen may be incorporated into the *Listeria* that will result in an anti-idiotype immune response to such B cells and/or the antibodies reacting with self antigens in an autoimmune disease.

[0163] In other embodiments of the invention, the antigen is derived from a human or animal pathogen. The pathogen is optionally a virus, bacterium, fungus, or a protozoan. In one embodiment, the antigen is a protein produced by the pathogen, or a fragment and/or variant of a protein produced by the pathogen.



[0164] For instance, the antigen may be derived from Human Immunodeficiency virus (such as gp 120, gp 160, gp41, gag antigens such as p24gag and p55gag, as well as proteins derived from the pol, env, tat, vif, rev, nef, vpr, vpu and LTR regions of HIV), Feline Immunodeficiency virus, or human or animal herpes viruses. In one embodiment, the antigen is derived from herpes simplex virus (HSV) types 1 and 2 (such as gD, gB, gH, Immediate Early protein such as ICP27), from cytomegalovirus (such as gB and gH), from Epstein-Barr virus or from Varicella Zoster Virus (such as gpI, II or III). (See, e. g., Chee et al. (1990) Cytomegaloviruses (J. K. McDougall, ed., Springer Verlag, pp. 125-169; McGeoch et al. (1988) J. Gen. Virol. 69: 1531-1574; U.S. Pat. No. 5,171,568; Baer et al. (1984) Nature 310: 207-211; and Davison et al. (1986) J. Gen. Virol. 67: 1759-1816.)

[0165] In another embodiment, the antigen is derived from a hepatitis virus such as hepatitis B virus (for example, Hepatitis B Surface antigen), hepatitis A virus, hepatitis C virus, delta hepatitis virus, hepatitis E virus, or hepatitis G virus. See, e. g., WO 89/04669; WO 90/11089; and WO 90/14436. The hepatitis antigen can be a surface, core, or other associated antigen. The HCV genome encodes several viral proteins, including E1 and E2. See, e. g., Houghton et al., *Hepatology* 14: 381-388(1991).

[0166] An antigen that is a viral antigen is optionally derived from a virus from any one of the families Picomaviridae (e. g., polioviruses, rhinoviruses, etc.); Caliciviridae; Togaviridae (e. g., rubella virus, dengue virus, etc.); Flaviviridae; Coronaviridae; Reoviridae (e. g., rotavirus, etc.); Birnaviridae; Rhabdoviridae (e. g., rabies virus, etc.); Orthomyxoviridae (e. g., influenza virus types A, B and C, etc.); Filoviridae; Paramyxoviridae (e. g., mumps virus, measles virus, respiratory syncytial virus, parainfluenza virus, etc.); Bunyaviridae; Arenaviridae; Retroviridae (e. g., HTLV-I; HTLV-11; HIV-1; HIV11b; HIVSF2; HTVLAV; HIVLAI; HIVMN; HIV-1CM235; HIV-2; simian immunodeficiency virus (SIV)); Papillomavirus, the tick-borne encephalitis viruses; and the like. See, e. g. *Virology*, 3rd Edition (W. K. Joklik ed. 1988); *Fundamental Virology*, 3rd Edition (B. N. Fields, D. M. Knipe, and P.M. Howley, Eds. 1996), for a description of these and other viruses. In one embodiment, the antigen is Flu-HA (Morgan et al., J. Immunol. 160:643 (1998)).

[0167] In some alternative embodiments, the antigen is derived from bacterial pathogens such as Mycobacterium, *Bacillus*, *Yersinia*, *Salmonella*, *Neisseria*, *Borrelia* (for example, OspA or OspB or derivatives thereof), *Chlamydia*, or *Bordetella* (for example, P.69, PT and FHA), or derived from parasites such as plasmodium or *Toxoplasma*. In one embodiment, the antigen is derived from the *Mycobacterium tuberculosis* (e.g. ESAT-6, 85A,

85B, 72F), *Bacillus anthracis* (e.g. PA), or *Yersinia pestis* (e.g. F1, V). In addition, antigens suitable for use in the present invention can be obtained or derived from known causative agents responsible for diseases including, but not limited to, Diphtheria, Pertussis, Tetanus, Tuberculosis, Bacterial or Fungal Pneumonia, Otitis Media, Gonorrhea, Cholera, Typhoid, Meningitis, Mononucleosis, Plague, Shigellosis or Salmonellosis, Legionaire's Disease, Lyme Disease, Leprosy, Malaria, Hookworm, Onchocerciasis, Schistosomiasis, Trypanosomiasis, Leishmaniasis, Giardia, Amoebiasis, Filariasis, Borelia, and Trichinosis. Still further antigens can be obtained or derived from unconventional pathogens such as the causative agents of kuru, Creutzfeldt-Jakob disease (CJD), scrapie, transmissible mink encephalopathy, and chronic wasting diseases, or from proteinaceous infectious particles such as prions that are associated with mad cow disease.

[0168] In still other embodiments, the antigen is obtained or derived from a biological agent involved in the onset or progression of neurodegenerative diseases (such as Alzheimer's disease), metabolic diseases (such as Type I diabetes), and drug addictions (such as nicotine addiction). Alternatively, the compositions comprising the antigen-expressing mutant *Listeria* strain is used for pain management and the antigen is a pain receptor or other agent involved in the transmission of pain signals.

[0169] In some embodiments, the antigen sequence may be codon-optimized to match the codon preference of the *Listerial* host expressing the antigen. In addition, the sequence encoding a signal peptide fused to the antigenic peptide may also be codon-optimized to match the codon preference of the *Listerial* host. For further information on codon optimization of antigens and signal sequences in *Listeria*, see U.S. Provisional application no. 60/532,598, filed on December 24, 2003, incorporated by reference herein.

#### **D. Immunogenicity of the attenuated *Listeria***

[0170] In some embodiments, the attenuated *Listeria* (e.g., mutant *Listeria* strains) are capable of inducing an immune response in a host animal. In one embodiment, the immune response is a cell-mediated immune response. In one embodiment, the effective immune response induced by the attenuated *Listeria* bacterium comprises a T cell response, such as a CD4+ T cell response or a CD8+ T cell response, or both.

[0171] These immune cell responses can be measured by both *in vitro* and *in vivo* methods to determine if the immune response of the *Listeria* involved in the present invention is effective. Efficacy can be determined by comparing these measurements for attenuated *Listeria* to those for non-attenuated *Listeria* for any particular antigen or heterologous

protein. One possibility is to measure the presentation of the protein or antigen of interest by an antigen-presenting cell that has been mixed with a population of the *Listeria*. The *Listeria* may be mixed with a suitable antigen presenting cell or cell line, for example a dendritic cell, and the antigen presentation by the dendritic cell to a T cell that recognizes the protein or antigen can be measured. If the *Listeria* are expressing the protein or antigen at a sufficient level, it will be processed into peptide fragments by the dendritic cells and presented in the context of MHC class I or class II to T cells. For the purpose of detecting the presented protein or antigen, a T cell clone or T cell line responsive to the particular protein or antigen may be used. The T cell may also be a T cell hybridoma, where the T cell is immortalized by fusion with a cancer cell line. Such T cell hybridomas, T cell clones, or T cell lines can comprise either CD8+ or CD4+ T cells. The dendritic cell can present to either CD8+ or CD4+ T cells, depending on the pathway by which the antigens are processed. CD8+ T cells recognize antigens in the context of MHC class I while CD4+ recognize antigens in the context of MHC class II. The T cell will be stimulated by the presented antigen through specific recognition by its T cell receptor, resulting in the production of certain proteins, such as IL-2, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), or interferon- $\gamma$  (IFN- $\gamma$ ), that can be quantitatively measured (for example, using an ELISA assay, ELISPOT assay, or Intracellular Cytokine Staining (ICS)). For specific examples of assays measuring immunogenicity, see Examples 5-7 below.

[0172] Alternatively, a hybridoma can be designed to include a reporter gene, such as  $\beta$ -galactosidase, that is activated upon stimulation of the T cell hybridoma by the presented antigens. The increase in the production of  $\beta$ -galactosidase can be readily measured by its activity on a substrate, such as chlorophenol red-B-galactoside, which results in a color change. The color change can be directly measured as an indicator of specific antigen presentation.

[0173] Additional *in vitro* and *in vivo* methods for assessing the antigen expression of *Listeria* vaccines of the present invention are known to those of ordinary skill in the art. It is also possible to directly measure the expression of a particular heterologous antigen by *Listeria*. For example, a radioactively labeled amino acid can be added to a cell population and the amount of radioactivity incorporated into a particular protein can be determined. The proteins synthesized by the cell population can be isolated, for example by gel electrophoresis or capillary electrophoresis, and the amount of radioactivity can be quantitatively measured to assess the expression level of the particular protein. Alternatively, the proteins can be expressed without radioactivity and visualized by various methods, such as an ELISA assay

or by gel electrophoresis and Western blot with detection using an enzyme linked antibody or fluorescently labeled antibody.

[0174] Additionally, in some embodiments the attenuated *Listeria* (e.g., mutant *Listeria* strains) expressing heterologous or autologous antigens induce *in vivo* cytotoxicity against cells expressing and/or bearing the antigens (see, e.g., Example 3, below). In some embodiments, the attenuated *Listeria* that express the heterologous or autologous antigens are therapeutically effective (see, e.g., Example 4, below).

[0175] While it is possible that the modification of the *Listeria* may reduce the level of protein expression as compared to non-attenuated *Listeria*, it is understood that in some embodiments the attenuated *Listeria* is still be effective in an immunogenic composition or vaccine. It is the combination of attenuation of non-phagocytic invasion with adequate protein expression that is important in some embodiments of the invention. The efficacy of a vaccine is generally related to the dose of antigen that can be delivered by the microbe. The attenuation of non-phagocytic invasion of the *Listeria* may be several logs while the *Listeria* gene expression is still adequately maintained. If the same dose of an attenuated *Listeria* is compared to that of a *Listeria* without the attenuating modification, the resulting antigen expression (as assessed by the methods discussed above) in the attenuated *Listeria* population is at least 1%, 5%, 10%, 25%, 50%, 75% or at least 90% of the antigen expression in the *Listeria* population without the attenuating modification. Since there may be several log attenuation in non-phagocytic invasion, the dose of the attenuated *Listeria* may be safely increased by up to several log, resulting in a greater amount of the antigen presented by the attenuated *Listeria* relative to *Listeria* without the attenuating modification upon vaccination.

### III. Vaccines and other compositions comprising the attenuated *Listeria*.

[0176] In addition to the attenuated *Listeria* described herein, the present invention provides a variety of compositions comprising the attenuated *Listeria*, including immunogenic compositions, pharmaceutical compositions, cells, and vaccines. (Exemplary attenuated *Listeria* useful in the compositions of the present invention are described in Section II.A-C, above, and in the Examples, below.)

[0177] For instance, the invention provides a pharmaceutical composition comprising (a) an attenuated *Listeria* bacterium which is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-*Listerial* antigen, and (b) a pharmaceutically acceptable excipient. The invention further provides a pharmaceutical composition comprising (a) an attenuated *Listeria* bacterium which is attenuated for entry

into non-phagocytic cells and for cell-to-cell spread, and (b) a pharmaceutically acceptable carrier.

[0178] The invention also provides a pharmaceutical composition comprising a mutant *Listeria* strain and a pharmaceutically acceptable carrier, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells. In one embodiment, the mutant *Listeria* strain is defective with respect to internalin B. In another embodiment, the genome of the mutant strain comprises at least one mutation in at least one gene encoding an invasin, such as an internalin like internalin B. In another embodiment the coding sequence (or gene) of *inlB* has been deleted from the genome of the strain. In still another embodiment, the coding sequences (or genes) of both *inlB* and *actA* has been deleted. A variety of pharmaceutically acceptable carriers suitable for use with bacterial strains are known to those of ordinary skill in the art.

[0179] The invention also provides a method of decreasing the toxicity of a pharmaceutical composition comprising a first strain of *Listeria* for administration to a host, comprising substituting the first strain with a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to the first *Listeria* strain, but retains an ability to enter phagocytic cells. In some embodiments, the mutant strain is defective with respect to internalin B. In other embodiments, the mutant strain is defective with respect to both internalin B and ActA.

[0180] The invention also provides immunogenic compositions comprising the attenuated *Listeria* described herein. For instance, the invention provides an immunogenic composition comprising an attenuated *Listeria* bacterium which is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-Listerial antigen. The invention further provides an immunogenic composition comprising an attenuated *Listeria* bacterium that is attenuated for entry into non-phagocytic cells and for cell-to-cell spread.

[0181] In addition, the invention provides an immunogenic composition comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells, and comprises a heterologous nucleic acid molecule encoding an antigen. In some embodiments, the strain is defective with respect to internalin B and comprises a heterologous nucleic acid molecule encoding an antigen. In other embodiments, the mutant strain is defective with respect to both internalin B and ActA.

[0182] The invention also provides a variety of vaccine compositions comprising the attenuated *Listeria* described herein. For instance, the invention provides a vaccine comprising (a) an attenuated *Listeria* bacterium which is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-*Listerial* antigen, and (b) a pharmaceutically acceptable carrier and/or an adjuvant.. The invention further provides a vaccine comprising (a) an attenuated *Listeria* bacterium that is attenuated for entry into non-phagocytic cells and for cell-to-cell spread, and (b) a pharmaceutically acceptable carrier and/or an adjuvant. The invention also provides a vaccine comprising (a) an attenuated *Listeria* bacterium which is attenuated for entry into non-phagocytic cells, and (b) a pharmaceutically acceptable carrier or an adjuvant. In some embodiments, the vaccines described herein comprise more than one type of attenuated *Listeria* bacterium. For instance, in some embodiments, the vaccine comprises multiple different types of attenuated *Listeria*. The different types of attenuated *Listeria* may differ from each other with respect to the antigens they express and/or the nature of their modifications and mutations.

[0183] The present invention further provides a vaccine comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells. In some embodiments, the strain is defective with respect to internalin B. In other embodiments, the mutant strain in the vaccine is defective with respect to both internalin B and ActA. In some embodiments, the vaccine comprises more than one mutant *Listeria* strain, each of is attenuated for entry into non-phagocytic cells.

[0184] The term vaccine as used herein is intended to encompass a prophylactic vaccine, such as one given to induce an immune response prior to exposure to an agent encompassing an antigen in order to permit the individual to mount a stronger immune response upon exposure to that antigen, therefore increasing its ability to resist the agent or cells carrying the agent. The term vaccine is also intended to encompass a therapeutic vaccine, such as one administered to an individual that already has a disease associated with the vaccine antigen, wherein the vaccine can boost the individual's immune response to the antigen to provide an increased ability to combat the disease or cells carrying the antigen.

[0185] Methods of administration of such a vaccine composition are known in the art, and include *in vitro*, oral, intravenous, intradermal, intraperitoneal, intramuscular, intralymphatic, intranasal and subcutaneous routes of administration. The vaccine compositions may further comprise additional components known in the art to improve the immune response to a vaccine, such as adjuvants or co-stimulatory molecules. For instance,

co-stimulatory molecules comprise one or more factors selected from the group consisting of GM-CSF, IL-2, IL-12, IL-14, IL-15, B7.1, B7.2, and B7-DC are optionally included in the vaccine compositions of the present invention. Other co-stimulatory molecules are known to those of ordinary skill in the art.

[0186] Vaccine formulations are known in the art and may include numerous additives, such as preservatives, stabilizers, adjuvants, antibiotics, and other substances. Stabilizers, such as lactose or monosodium glutamate (MSG), are added to stabilize the vaccine formulation against a variety of conditions, such as temperature variations or a freeze-drying process. Vaccine formulations may also include a suspending fluid such as sterile water or saline. In some embodiments, the vaccine is a frozen or lyophilized formulation comprising one or more pharmaceutically acceptable excipients that are suitable for parenteral or oral administration. In other embodiments, the vaccine is a frozen or lyophilized formulation comprising one or more pharmaceutically acceptable excipients that are suitable for mucosal administration or administration as an aerosol.

[0187] The efficacy of the vaccines may be evaluated using *in vivo* models, for example a mouse model. Vaccines can be evaluated for their ability to provide either a prophylactic or therapeutic effect against a particular disease. For example, in the case of infectious diseases, a population of mice can be vaccinated with a desired amount of the appropriate vaccine of the invention, where the bacterium expresses an infectious disease associated antigen. This antigen can be from the *Listeria* itself or can be a heterologous antigen. The mice can be subsequently infected with the infectious agent related to the vaccine antigen and assessed for protection against infection. The progression of the infectious disease can be observed relative to a control population (either non-vaccinated or vaccinated with vehicle only or *Listeria* that does not express the appropriate antigen).

[0188] In the case of cancer vaccines, tumor cell models are available, where a tumor cell line expressing a desired tumor antigen can be injected into a population of mice either before (therapeutic model) or after (prophylactic model) vaccination with a *Listeria* involved in the invention containing the desired tumor-associated antigen or an antigen derived from a tumor-associated antigen. Vaccination with a *Listeria* containing the tumor antigen can be compared to control populations that are either not vaccinated, vaccinated with vehicle, or with a *Listeria* that does not express the desired antigen. The effectiveness of the vaccine in such models can be evaluated in terms of tumor volume as a function of time after tumor injection or in terms of survival populations as a function of time after tumor injection. Generally, the vaccine will result in a reduced tumor volume at most or all time points

relative to a negative control (such as a non-vaccinated sample) and will result in a longer median survival.

[0189] In some embodiments of the invention, the tumor volume in those mice vaccinated with the mutant *Listeria* is less than or equal to the tumor volume of the control mice. In one embodiment, the tumor volume in mice vaccinated with mutant *Listeria* is at least approximately the same as the tumor volume in the control mice. In another embodiment, the tumor volume in mice vaccinated with mutant *Listeria* is at least about 10%, at least about 20%, at least about 30%, at least about 40% or at least about 50% less than the tumor volume in the control mice. In another embodiment, this differential in tumor volume is observed at least 7, 14, 30, or at least 60 days following the implant of the tumors into the mice. In one embodiment, the median survival time in the mice vaccinated with mutant *Listeria* is approximately the same as that in mice vaccinated with control *Listeria*. In another embodiment, the median survival time in the mice vaccinated with attenuated *Listeria* is at least about 1, at least about 3, or at least about 5 days longer than in mice vaccinated with control *Listeria*. In other embodiments, the median survival time in the mice vaccinated with attenuated *Listeria* is at least about 10 days, at least about 20 days, at least about 30 days longer than in mice vaccinated with control *Listeria*. In one embodiment of the invention, the vaccination with the mutant *Listeria* is done at a dose of *Listeria* that is approximately the same as the dose of control *Listeria*. In another embodiment, the vaccination of mutant *Listeria* is safely dosed at a level that is at least about 2, about 5, about 10, about  $10^2$ , about  $10^3$ , or at least about  $10^4$  fold higher than the vaccination dose of control *Listeria*.

[0190] In addition to measurements of the efficacy of the vaccines, measurements of the safety and toxicity can also be made. Such methods of measuring safety can include determining the number of mutant *Listeria* entering hepatocytes as compared to non-mutant *Listeria*. In some embodiments, the mutant *Listeria* is defective with respect to internalin B. In other embodiments, the mutant *Listeria* is defective with respect to both internalin B and ActA.

[0191] In another aspect, the invention provides a method of decreasing the pathogenicity of a strain of *Listeria* used in a vaccine, comprising modifying the strain so as to decrease the ability of the strain to enter non-phagocytic cells, but substantially retain the ability of the strain to enter phagocytic cells. In some embodiments, the invention provides a method of decreasing the pathogenicity of a strain of *Listeria* used in a vaccine, comprising



modifying the strain so as to make it defective with respect to internalin B. In some embodiments, the strain is further modified to be defective with respect to ActA.

[0192] In other aspects, the invention provides methods of making vaccines. For instance, the invention provides a method of making a vaccine comprising contacting attenuated *Listeria* (such as a mutant strain of *Listeria*) with a professional antigen-presenting cell, under suitable conditions and for a time sufficient to load the professional antigen-presenting cells, wherein the *Listeria* is attenuated for entry into non-phagocytic cells relative to a non-modified *Listeria* such as wild type (e.g., defective with respect to internalin B), but retains an ability to enter phagocytic cells, and comprises a heterologous nucleic acid molecule encoding an antigen. In still another aspect, the invention provides a professional antigen-presenting cell comprising a *Listeria* bacterium, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells. The invention also provides a professional antigen-presenting cell comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells. In some embodiments, the mutant *Listeria* is contacted with the professional antigen-presenting cell *ex vivo* or *in vivo*. In some embodiments, the professional antigen-presenting cell is a dendritic cell. In other embodiments, the professional antigen-presenting cell is a macrophage. For descriptions of some exemplary antigens, see Section II.C, above.

#### IV. Methods of inducing immune responses and methods of treatment

[0193] The present invention also provides methods of inducing immune responses and treating and/or preventing disease comprising the use of the attenuated *Listeria*, cells, compositions, and vaccines described herein. (Exemplary attenuated *Listeria* useful in the methods of the present invention are described in Section II.A-D, above, and in the Examples, below. Exemplary compositions, vaccines, and cells are described in Section III, above.)

[0194] For instance, the invention provides a method of inducing an immune response in a host to a non-Listerial antigen comprising administering to the host an effective amount of a composition comprising a *Listeria* bacterium that is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding the non-Listerial antigen. The invention also provides a method of inducing an immune response in a host to an antigen comprising administering to the host an effective amount of a composition comprising a *Listeria* bacterium that is attenuated both for entry into non-phagocytic cells and for cell-to-

cell spread, wherein the mutant *Listeria* strain comprises a nucleic acid encoding the antigen. The invention further provides a method of inducing an immune response in a host to an antigen, comprising administering to the host an effective amount of a vaccine comprising (a) a *Listeria* bacterium that is attenuated for entry into non-phagocytic cells, and (b) a pharmaceutically acceptable carrier and/or an adjuvant.

[0195] The invention also provides a method of inducing an immune response to an antigen in a host comprising administering to the host an effective amount of a composition comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells, and comprises a nucleic acid molecule encoding the antigen. The immune response may be a cell-mediated response. In one embodiment, the immune response is a CD8+ T-cell response. In another embodiment, the immune response is a CD4+ T-cell response. In still another embodiment, the immune response induced in the host comprises both a CD8+ and CD4+ T-cell response. For descriptions of some exemplary antigens, see Section II.C, above. In one embodiment the antigen is a tumor-associated antigen or derived from a tumor-associated antigen. In some embodiments, the mutant strain is defective with respect to internalin B. In other embodiments, the mutant strain is defective with respect to both internalin B and ActA.

[0196] In another aspect, the invention provides a method of inducing MHC class I antigen presentation on a professional antigen-presenting cell (*in vitro*, *in vivo*, or *ex vivo*) comprising contacting a mutant *Listeria* strain with the professional antigen-presenting cell, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells, and comprises a heterologous nucleic acid molecule encoding an antigen comprising an MHC class I epitope. In some embodiments, the mutant strain is defective with respect to internalin B. In other embodiments, the mutant strain is defective with respect to both internalin B and ActA.

[0197] Additionally, the invention provides a method of inducing MHC class I antigen presentation or MHC class II antigen presentation on an antigen-presenting cell (either *in vivo* or *in vitro*), comprising contacting a *Listeria* bacterium with an antigen-presenting cell, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-Listerial antigen comprising an MHC class I epitope or an MHC class II epitope. The invention further provides a method of inducing MHC class II antigen presentation on a professional antigen-presenting cell (*in vitro*, *in vivo*, or *ex vivo*) comprising contacting a mutant *Listeria* strain with the professional

antigen-presenting cell, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells, and comprises a heterologous nucleic acid molecule encoding an antigen comprising an MHC class II epitope. In some embodiments, the mutant strain is defective with respect to internalin B. In other embodiments, the mutant strain is defective with respect to both internalin B and ActA.

[0198] The invention also provides a method of inducing an immune response in a host to an antigen comprising administering to the host an effective amount of a professional antigen-presenting cell comprising an attenuated *Listeria* bacterium, wherein the attenuated *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid encoding the antigen.

[0199] The invention further provides a method of inducing an immune response in a host to an antigen, comprising the following steps: (a) contacting an attenuated *Listeria* bacterium with an antigen-presenting cell from the host, under suitable conditions and for a time sufficient to load the antigen-presenting cells, wherein the attenuated *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding the antigen; and (b) administering the antigen-presenting cell to the host. The invention also provides a method of inducing an immune response in a host to an antigen comprising the following steps: (a) contacting a mutant *Listeria* strain with a professional antigen-presenting cell from the host, under suitable conditions and for a time sufficient to load the antigen-presenting cells, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells, and comprises a nucleic acid molecule encoding an antigen; and (b) administering the antigen-presenting cell to the host. In one embodiment, the antigen is a tumor-associated antigen or is derived from a tumor-associated antigen. In some embodiments, the mutant strain is defective with respect to internalin B. In other embodiments, the mutant strain is defective with respect to both internalin B and ActA.

[0200] In a further aspect, the invention provides a method of selectively delivering a heterologous protein into phagocytic cells in a host, comprising administering to the host a composition comprising a mutant *Listeria* strain that is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but substantially retains an ability to enter phagocytic cells, wherein the genome of the mutant *Listeria* strain comprises at least one mutation in at least one gene encoding an invasin, such as an internalin.

[0201] The invention further provides methods of preventing or treating disease (such as cancer, an infectious disease, or Listeriosis) in a host using the attenuated *Listeria* described herein. For instance, the invention provides a method of preventing or treating disease in a host comprising administering to the host an effective amount of a composition comprising an attenuated *Listeria* bacterium that is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-Listerial antigen. The invention also provides a method of preventing or treating disease in host comprising administering to the host an effective amount of a composition comprising an attenuated *Listeria* bacterium which is attenuated both for entry into non-phagocytic cells and for cell-to-cell spread. The invention further provides a method of preventing or treating disease in a host, comprising administering to the host an effective amount of a vaccine comprising (a) an attenuated *Listeria* bacterium which is attenuated for entry into non-phagocytic cells, and (b) a pharmaceutically acceptable carrier and/or an adjuvant.

[0202] In one aspect, the present invention provides a method of preventing or treating disease in a host, comprising administering to the host a vaccine comprising a mutant *Listeria* strain, wherein the mutant *Listeria* strain is attenuated for entry into non-phagocytic cells relative to a non-mutant *Listeria* strain, but retains an ability to enter phagocytic cells. The disease is prevented or treated by the induction of a therapeutically beneficial immune response against an antigen related to the disease. In some embodiments, the mutant strain is defective with respect to internalin B. In other embodiments, the mutant strain is defective with respect to both internalin B and ActA. In one embodiment, the disease is cancer. In another embodiment, the disease is an autoimmune disease. In still other embodiments, the disease is an infectious disease or another disease caused by a pathogen such as a virus, bacterium, fungus, or protozoa.

[0203] The invention also provides a method of preventing or treating disease in a host comprising administering to the host an effective amount of a professional antigen-presenting cell comprising an attenuated *Listeria* bacterium, wherein the attenuated *Listeria* bacterium is attenuated for entry into non-phagocytic cells.

[0204] The invention further provides a composition comprising a *Listeria* bacterium for medical use, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-Listerial antigen. In another embodiment, the invention provides a *Listeria* bacterium for medical use, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-Listerial antigen.

[0205] The invention also provides a composition comprising a *Listeria* bacterium for medical use, wherein the bacterium is attenuated both for entry into non-phagocytic cells. The invention also provides a *Listeria* bacterium for medical use, wherein the bacterium is attenuated both for entry into non-phagocytic cells.

[0206] In addition, the invention provides a composition comprising a *Listeria* bacterium for medical use, wherein the bacterium is attenuated both for entry into non-phagocytic cells and for cell-to-cell spread. The invention also provides a *Listeria* bacterium for medical use, wherein the bacterium is attenuated both for entry into non-phagocytic cells and for cell-to-cell spread.

[0207] Additionally, the invention provides the use of a *Listeria* bacterium for the manufacture of a medicament for treatment of a disease unrelated to and/or not caused by *Listeria*, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-*Listerial* antigen. For instance, in some embodiments, the disease is cancer and the antigen is a tumor antigen or is an antigen derived from a tumor antigen.

[0208] The invention also provides the use of a *Listeria* bacterium for the manufacture of a medicament for treatment of a disease unrelated to and/or not caused by *Listeria*, wherein the bacterium is attenuated for entry into non-phagocytic cells. In some embodiments, the *Listeria* bacterium is further attenuated for cell-to-cell spread. In some embodiments, the disease is cancer and the antigen is a tumor antigen or is an antigen derived from a tumor antigen.

[0209] In some embodiments, the use of the attenuated *Listeria* in the prophylaxis or treatment of a cancer comprises the delivery of the attenuated *Listeria* to cells of the immune system of an individual to prevent or treat a cancer present or to which the individual has increased risk factors, such as environmental exposure and/or familial disposition. In some embodiments, the individual who is treated with the vaccine has had a tumor removed and/or has had cancer in the past.

[0210] The delivery of the attenuated *Listeria*, or a composition comprising the attenuated *Listeria*, may be by any suitable method, including, but not limited to, intradermal, subcutaneous, intraperitoneal, intravenous, intramuscular, intralymphatic, oral or intranasal. In some embodiments delivery of the attenuated *Listeria* is parenteral. In some embodiments, mucosal delivery is used.

[0211] In some embodiments, the compositions comprising the attenuated *Listeria* are administered to a host in combination with an immunostimulatory agent. The attenuated

*Listeria* and the immunostimulatory agent can be administered simultaneously, sequentially or separately. Examples of immunostimulatory agents include, but are not limited to IL-2, IL-12, GMCSF, IL-15, B7.1, B7.2, and B7-DC and IL-14. In some embodiments, the immunostimulatory agent is an antibody or small molecule that targets T-cell regulatory molecules. For instance, in some embodiments, the immunostimulatory agent is CTLA-4 or BTLA-4. In some embodiments, the immunostimulatory agent is an agent that targets regulatory T-cells. For instance, the immunostimulatory agent used in conjunction with the attenuated *Listeria* may be an anti-CD25 antibody, an anti-LAG-3 antibody, or cytoxin.

[0212] The host in the methods described herein, is any vertebrate, preferably a mammal, including domestic animals, sport animals, and primates, and including humans.

[0213] The dosage of the pharmaceutical compositions or vaccines that are given to the host will vary depending on the species of the host, the size of the host, and the condition or disease of the host. The dosage of the compositions will also depend on the frequency of administration of the compositions and the route of administration. In some embodiments, a single dose comprises from about  $10^2$  to about  $10^{12}$  of the attenuated *Listeria* organisms. In another embodiment, a single dose comprises from about  $10^6$  to about  $10^{11}$  of the attenuated *Listeria* organisms. In still another embodiment, a single dose of the pharmaceutical composition or vaccine comprises from about  $10^7$  to about  $10^{10}$  of the attenuated organisms.

## V. Kits

[0214] The invention further provides kits (or articles of manufacture) comprising the attenuated *Listeria* of the invention (as described above and in the Examples below).

[0215] In one aspect, the invention provides a kit comprising (a) a composition comprising a *Listeria* bacterium, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-Listerial antigen; and (b) instructions for the use of the composition in the prevention or treatment of a disease in a host. In some embodiments, the instructions are on a label on or in the kit. In other embodiments, the instructions are on an insert contained within the kit.

[0216] In another aspect, the invention provides a kit comprising (a) a composition comprising a *Listeria* bacterium, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-Listerial antigen; and (b) instructions for the administration of the composition to a host. In some embodiments, the instructions are on a label on or in the kit. In other embodiments, the instructions are on an insert contained within the kit. In some embodiments, the instructions

are on a label on or in the kit. In other embodiments, the instructions are on an insert contained within the kit.

[0217] In still another aspect, the invention provides a kit comprising (a) a composition comprising the *Listeria* bacterium, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells; and (b) instructions for the use of the composition in the prevention or treatment of a disease in a host. In some embodiments, the *Listeria* bacterium is further attenuated for cell-to-cell spread. In some embodiments, the instructions are on a label on or in the kit. In other embodiments, the instructions are on an insert contained within the kit.

[0218] The invention further provides a kit comprising (a) a composition comprising the *Listeria* bacterium, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells; and (b) instructions for the administration of the composition to a host. In some embodiments, the *Listeria* bacterium is further attenuated for cell-to-cell spread. In some embodiments, the instructions are on a label on or in the kit. In other embodiments, the instruction are on an insert contained within the kit.

## EXAMPLES

[0219] The following examples are provided to illustrate, but not to limit, the invention.

### Example 1. Construction of mutant *Listeria* strains.

#### *A. Preparation of mutant *Listeria* strains.*

[0220] *Listeria* strains were derived from 10403S (Bishop et al., *J. Immunol.* 139:2005 (1987)). *Listeria* strains with in-frame deletions of the indicated genes were generated by SOE-PCR and allelic exchange with established methods (Camilli, et al, *Mol. Microbiol.* 8:143 (1993)). The mutant strain LLO L461T (DP-L4017) was described in Glomski, et al, *J. Cell. Biol.* 156: 1029 (2002), incorporated by reference herein. The  $\Delta actA$  mutant (DP-L4029) is the DP-L3078 strain described in Skoble et al., *J. of Cell Biology*, 150: 527-537 (2000), incorporated by reference herein in its entirety, which has been cured of its prophage. (Prophage curing is described in (Lauer et al., *J. Bacteriol.* 184:4177 (2002); U.S. Patent Publication No. 2003/0203472).) The LLO mutant (DP-L4027) (Lauer et al., *J. of Bacteriology*, 184:4177-4186 (2002)), and LLO  $\Delta 26$  (DP-L4042) (Decatur et al, *Science* 290:992 (2000)) were also described previously. Construction of an  $\Delta actA\Delta uvrAB$  strain is

described in the copending U.S. provisional application 60/446,051, filed February 6, 2003, as L4029/*uvrAB* (see, e.g. Example 7 of that application). DP-L4029/*uvrAB* (also known as  $\Delta actA \Delta uvrAB$  or *actA'uvrAB*) was deposited with ATCC October 3, 2003, assigned PTA-5563.

B. Construction of *pKSV7-dl inlB* for deletion of *inlB* from *Listeria* by allelic exchange.

[0221] Deletion of *inlB* from *Listeria* DP-L4029 (or from other selected mutant strains or from wild-type *Listeria*) can be effected by allelic exchange, as described by Camilli et al., *Mol. Microbiol.* 8:143-147 (1993). Splice Overlap Extension (SOE) PCR can be used to prepare the construct used in the allelic exchange procedure. The source of the internalin B gene is the sequence listed as Genbank accession number AL591975 (*Listeria monocytogenes* strain EGD, complete genome, segment 3/12; *inlB* gene region: nts. 97008-98963), incorporated by reference herein in its entirety, and/or the sequence listed as Genbank accession number NC\_003210 (*Listeria monocytogenes* strain EGD, complete genome, *inlB* gene region: nts. 457008-458963), incorporated by reference herein in its entirety.

[0222] In the primary PCR reactions, approximately 1000 bps of sequence upstream and downstream from the *Listeria inlB* gene 5' and 3' ends, respectively, are amplified using the following template and primers:

Template: DP-L4056 or DP-L4029 genomic DNA

Primer pair 1 (For amplification of region upstream from 5' end of *inlB*):

Lm-96031F: 5'-GTTAAGTTTCATGTGGACGGCAAAG (SEQ ID NO:2)

( $T_m$ : 72°C)

Lm-(3' *inlB*-R +) 97020R: 5'-

AGGTCTTTTTCAGTTAACTATCCTCTCCTTGATTCTAGTTAT

(SEQ ID NO:3) ( $T_m$ : 114°C)

(The underlined sequence complementary to region downstream of *InlB* carboxy terminus.)

Amplicon Size (bps): 1007

Primer pair 2 (For amplification of region downstream from 3' end of *inlB*):

Lm-(5' *inlB*-F +) 98911F: 5'-

CAAGGAGAGGATAGTTAACTGAAAAAGACCTAAAAAAGAA

GGC (SEQ ID NO:4) ( $T_m$ : 118°C)



(The underlined sequence complementary to region upstream of *InlB* amino terminus.)

Lm-99970R: 5'-TCCCCTGTTCTATAATTGTTAGCTC (SEQ ID NO:5)  
(T<sub>m</sub>: 74°C)

Amplicon size (bps): 1074

[0223] In the secondary PCR reaction, the primary PCR amplicons are fused through SOE PCR, taking advantage of complementarity between reverse primer from pair 1 and the forward primer of pair 2. This results in precise deletion of *inlB* coding sequence: nts. 97021-98910=1889 bps. The following template and primers were utilized in the secondary PCR reaction:

*Template:* Cleaned primary PCR reactions

*Primer pair:*

Lm-96043F: 5'-GTGGACGGCAAAGAAACAACCAAAG (SEQ ID NO:6)  
(T<sub>m</sub>: 74°C)

Lm-99964R: 5'-GTTCTATAATTGTTAGCTCATTTTTTTC (SEQ ID NO:7) (T<sub>m</sub>: 74°C)

(Amplicon size (bps): 2033)

[0224] A protocol for completing the construction process is as follows:

[0225] The primary PCR reactions (3 temperature cycle) are performed using Vent DNA polymerase (NEB) and 10 µl of a washed 30°C *Listeria* DP-L4056 OR DP-L4029 overnight culture. The expected size of *Listeria* amplicons by 1% agarose gel (1007 bps and 1074 bps). The primary PCR reactions are gel purified and the DNA eluted with GeneClean (BIO 101).

[0226] A secondary PCR reaction is performed, utilizing approximately equal amounts of each primary reaction as template (ca. 5 µl). The expected size of the *Listeria* amplicon from the secondary PCR reaction is verified by 1% agarose gel (2033 bps). Adenosine residue are added at the 3' ends of *Listeria dl inlB* amplicon with Taq polymerase.

[0227] The *Listeria dl inlB* amplicon is then inserted into a pCR2.1-TOPO vector. The pCR2.1-TOPO-*dl inlB* plasmid DNA is digested with *XhoI* and *KpnI* and the 2123 bp fragment is gel purified. The *KpnI/XhoI* 2123 bp fragment is inserted into a pKSV7 vector that has been prepared by digestion with *KpnI* and *XhoI* and treatment with CIAP (pKSV7-*dl inlB*). The fidelity of *dl inlB* sequence in pKSV7-*dl inlB* is then verified. The *inlB* gene is deleted from desired *Listeria* strains by allelic exchange with pKSV7-*dl inlB* plasmid.

C. *Construction of antigen-expressing strains.*

[0228] Mutant *Listeria* strains expressing a truncated form of a model antigen ovalbumin (OVA), the immunodominant epitope from mouse colorectal cancer (CT26) known as AH1 (SPSYVYHQF (SEQ ID NO:8)), and the altered epitope AH1-A5 (SPSYAYHQF (SEQ ID NO:9); Slansky et al., *Immunity*, 13:529-538 (2000)) were prepared. The pPL2 integrational vector (Lauer et al., *J. Bacteriol.* 184:4177 (2002); U.S. Patent Publication No. 2003/0203472) was used to derive OVA and AH1-A5/OVA recombinant *Listeria* strains containing a single copy integrated into an innocuous site of the *Listeria* genome.

i. *Construction of OVA-expressing Listeria (DP-L4056).*

[0229] An antigen expression cassette consisting of hemolysin-deleted LLO fused with truncated OVA and contained in the pPL2 integration vector (pPL2/LLO-OVA) is first prepared. The *Listeria*-OVA vaccine strain is derived by introducing pPL2/LLO-OVA into the phage-cured *L. monocytogenes* strain DP-L4056 at the PSA (Phage from ScottA) attachment site tRNA<sup>Arg</sup>-attBB'.

[0230] PCR is used to amplify the hemolysin-deleted LLO using the following template and primers:

Source: DP-L4056 genomic DNA

Primers:

Forward (*KpnI*-LLO nts. 1257-1276):

5'-CTCTGGTACCTCCTTTGATTAGTATATTC (SEQ ID NO:10)

(T<sub>m</sub>: LLO-spec: 52°C. Overall: 80°C.)

Reverse (*BamHI*-*XhoI*-LLO nts. 2811-2792):

5'-CAATGGATCCCTCGAGATCATAATTTACTTCATCCC (SEQ ID NO:11)

(T<sub>m</sub>: LLO-spec: 52°C. Overall: 102°C.)

[0231] PCR is also used to amplify the truncated OVA using the following template and primers:

Source: pDP3616 plasmid DNA from DP-E3616 *E. coli* (Higgins et al., *Mol. Molbiol.* 31:1631-1641 (1999)).

Primers:

Forward (*XhoI*-*NcoI* OVA cDNA nts. 174-186):

5'-ATTTCTCGAGTCCATGGGGGTTCTCATCATC (SEQ ID NO:12)

(T<sub>m</sub>: OVA-spec: 60°C. Overall: 88°C.)

Reverse (*XhoI-NotI-HindIII*):

5'-GGTGCTCGAGTGCGGCCGCAAGCTT (SEQ ID NO:13)

(T<sub>m</sub>: Overall: 82°C.)

[0232] One protocol for completing the construction process involves first cutting the LLO amplicon with KpnI and BamHI and inserting the KpnI/BamHI vector into the pPL2 vector (pPL2-LLO). The OVA amplicon is then cut with *XhoI* and *NotI* and inserted into the pPL2-LLO which has been cut with *XhoI/NotI*. (Note: The pPL2 vector does not contain any *XhoI* sites; pDP-3616 contains one *XhoI* site, that is exploited in the OVA reverse primer design.) The construct pPL2/LLO-OVA is verified by restriction analysis (*KpnI-LLO-XhoI-OVA-NotI*) and sequencing. The plasmid pPL2/LLO-OVA is introduced into *E. coli* by transformation, followed by introduction and integration into *Listeria* (DP-L4056) by conjugation, exactly as described by Lauer et al. (or into another desired strain of *Listeria*, such as an  $\Delta inlB$  mutant or an  $\Delta actA \Delta inlB$  double mutant).

[0233] A description of the insertion of an antigen expression cassette that expresses OVA can also be found in Example 8 of the U.S. provisional application entitled "Free-Living Microbe Based Vaccine Compositions", US Serial No. 60/511,869, filed October 15, 2003.

ii. *Construction of Listeria strains expressing AH1/OVA or AH1-A5/OVA.*

[0234] To prepare *Listeria* expressing either the AH1/OVA or the AH1-A5/OVA antigen sequences, inserts bearing the antigen are first prepared from oligonucleotides and then ligated into the vector pPL2-LLO-OVA (prepared as described above).

[0235] The following oligonucleotides are used in preparation of the AH1 or AH1-A5 insert:

*AH1 epitope insert (ClaI-PstI compatible ends):*

Top strand oligo (AH1 Top):

5'-CGATTCCCCTAGTTATGTTTACCACCAATTTGCTGCA (SEQ ID NO:14)

Bottom strand oligo (AH1 Bottom):

5'-GCAAATTGGTGGTAAACATAACTAGGGGAAT (SEQ ID NO:15)

*AH1-A5 epitope insert (ClaI-AvaII compatible ends):*

The sequence of the AH1-A5 epitope is SPSYAYHQF (SEQ ID NO:9) (5'-AGT CCA AGT TAT GCA TAT CAT CAA TTT-3') (SEQ ID NO:16).

Top: 5'-CGATAGTCCAAGTTATGCATATCATCAATTTGC (SEQ ID NO:17)

Bottom: 5'-GTCGCAAATTGATGATATGCATAACTTGGACTAT (SEQ ID NO:18)

[0236] The oligonucleotide pair for a given epitope are mixed together at an equimolar ratio, heated at 95 °C for 5 min. The oligonucleotide mixture is then allowed to slowly cool. The annealed oligonucleotide pairs are then ligated at a 200 to 1 molar ratio with pPL2-LLO/OVA plasmid prepared by digestion with the relevant restriction enzymes. The identity of the new construct can be verified by restriction analysis and/or sequencing.

[0237] The plasmid can then be introduced into *E. coli* by transformation, followed by introduction and integration into *Listeria* (DP-L4056) by conjugation, exactly as described by Lauer et al. (or into another desired strain of *Listeria*, such as an  $\Delta inlB$  mutant or an  $\Delta actA\Delta inlB$  double mutant).

#### Example 2. *Listeria* pathogenicity studies.

[0238] The median lethal dose (LD<sub>50</sub>) of the some of the mutant *Listeria* strains was determined by IV infection of mice. Three to five female C57BL/6 mice were infected IV with three 5-fold dilutions of the indicated strain. The mice were monitored daily for 10 days and sacrificed when they showed signs of distress. The median lethal dose was calculated. The data is shown in Table 1, below. The results show that the mutant *Listeria* strains that are deficient with respect to internalin B ( $\Delta inlB$ ,  $\Delta actA\Delta inlB$ , and  $\Delta actA\Delta inlAB$ ) are less toxic when combined with an *actA* deletion. The  $\Delta inlB$  only strain shows toxicity similar to wild-type *Listeria*.

Table 1. Attenuated *Listeria monocytogenes* strains

Strain	Genotype	Phenotype	Pathogenicity LD <sub>50</sub> (cfu) in C57BL/6 mice
			Parental
DP-L4056	Wild type; 10403S, phage free	Wild-type	$1 \times 10^5$
DP-L4406	$\Delta inlB$	Impaired <i>inlB</i> -mediated infection	$1 \times 10^5$
DP-L4029	$\Delta actA$	Defective cell-to-cell spread	$1 \times 10^8$
	$\Delta actA \Delta inlB$	No host actin nucleation; defective cell-to-cell spread; impaired <i>inlB</i> - mediated infection	$1 \times 10^8$
	$\Delta actA \Delta inlAB$		$1 \times 10^9$

Example 3. Assessment of *in vivo* cytotoxic activity in mice vaccinated with *Listeria monocytogenes*.

[0239] A series of studies were done to assess the ability of vaccinated mice to lyse antigen specific target cells *in vivo*. In the first study, Balb/c mice were vaccinated either intravenously (IV) or intramuscularly (IM) with *Listeria monocytogenes* strains DP-L4029 ( $\Delta actA$ ), DP-L4029  $\Delta inlB$  ( $\Delta actA \Delta inlB$ ) and the same strains engineered to express AH1-A5 according to Table 2. The *Listeria* constructs expressing AH1-A5 also express hemolysin-deleted LLO and truncated OVA (see Example 1.C, above). The vaccination dose was 0.1 LD<sub>50</sub>. A target cell population was prepared by harvesting the spleens of 10 naïve Balb/c mice in RPMI 1640 medium. The cells were dissociated and the red cells lysed. The white blood cells were counted and split into two equal populations. Each group was pulsed with a specific peptide, either target (AH1, SPSYVYHQF (SEQ ID NO:8), from SynPep, Dublin, CA) or control ( $\beta$ -gal, TPHPARIGL (SEQ ID NO:19)), at 0.5  $\mu$ g/mL for 90 minutes at 37 °C. Cells were then washed 3 times in medium, and twice in PBS + 0.1% BSA. Cells were resuspended at  $1 \times 10^7$  per mL in warm PBS + 0.1% BSA (10 mL or less) for labeling with carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, Eugene, OR). To the target cell suspension, 1.25  $\mu$ L of a 5mM stock of CFSE was added and the sample mixed by vortexing. To the control cell suspension, a ten-fold dilution of the CFSE stock was added and the sample mixed by vortexing. The cells were incubated at 37 °C for 10 minutes.

Staining was stopped by addition of a large volume (>40 mL) of ice-cold PBS. The cells were washed twice at room temperature with PBS, then resuspended and counted. Each cell suspension was diluted to  $50 \times 10^6$  per mL, and 100  $\mu$ L of each population was mixed and injected via the tail vein of either naïve or vaccinated mice 6 days after vaccination. After 12-24 hours, the spleens were harvested and a total of  $5 \times 10^6$  cells were analyzed by flow cytometry. The high (target) and low (control) fluorescent peaks were enumerated, and the ratio of the two was used to establish the percentage of target cell lysis relative to the HBSS control population. The results are shown in Table 2 and Figure 1A. (The tables in this Example indicate the averages of the three mice, whereas the figures show representative histograms individual mice.) The vaccination using  $\Delta actA \Delta inlB$  vs. using  $\Delta actA$  shows an improvement in the antigen specific *in vivo* cytotoxicity when administered IV but not IM.

Table 2 *In vivo* cytotoxicity (% kill of target cells relative to a non vaccinated control sample) of Balb/c mice vaccinated as indicated.

Immunization	# of mice	Vaccination dose	% kill of target cells
HBSS	3	100 $\mu$ L IV	0
$\Delta actA$	3	$5 \times 10^6$ in 100 $\mu$ L IV	-0.1
$\Delta actA$ AH1-A5	3	$5 \times 10^6$ in 100 $\mu$ L IV	11.5
$\Delta actA \Delta inlB$	3	$1 \times 10^7$ in 100 $\mu$ L IV	1.7
$\Delta actA \Delta inlB$ AH1-A5	3	$1 \times 10^7$ in 100 $\mu$ L IV	23.5
$\Delta actA$	3	$5 \times 10^6$ in 100 $\mu$ L IM	1.5
$\Delta actA$ AH1-A5	3	$5 \times 10^6$ in 100 $\mu$ L IM	8.5
$\Delta actA \Delta inlB$	3	$1 \times 10^7$ in 100 $\mu$ L IM	2.8
$\Delta actA \Delta inlB$ AH1-A5	3	$1 \times 10^7$ in 100 $\mu$ L IM	8.7

[0240] Another study was done using the  $\Delta actA$  as well as  $\Delta actA \Delta inlB$  double mutant, both strains expressing AH1-A5, vaccinating IV according to Table 3. In this study, the naïve spleen cells were pulsed with  $\beta$ -gal, AH1, or P60-217 (KYGVSVQDI (SEQ ID NO:20), a *Listeria* specific control). The  $\beta$ -gal pulsed cells were labeled with low CFSE, the AH1 and P60-217 with high CFSE. Two mice of each set were injected at day 5 with  $\beta$ -gal

and AH-1 pulsed cells as above. The remaining two of each set were injected at day 5 with  $\beta$ -gal and P60-217 pulsed cells. The results are shown in Table 3 and Figure 1B.

Table 3. *In vivo* cytotoxicity (% kill of target cells relative to a non vaccinated control sample) of Balb/c mice vaccinated as indicated.

Immunization	# of mice	Vaccination dose	Target	% kill
HBSS	2	100 $\mu$ L	P60-217	0
$\Delta actA$ AH1-A5	2	$5 \times 10^6$ in 100 $\mu$ L	P60-217	62.4
$\Delta actA \Delta inlB$ AH1-A5	2	$1 \times 10^7$ in 100 $\mu$ L	P60-217	42.0
HBSS	2	100 $\mu$ L	AH1	0
$\Delta actA$ AH1-A5	2	$5 \times 10^6$ in 100 $\mu$ L	AH1	19.7
$\Delta actA \Delta inlB$ AH1-A5	2	$1 \times 10^7$ in 100 $\mu$ L	AH1	28.0

[0241] Another study was done using  $\Delta actA \Delta inlB$  double mutant with or without AH1-A5, vaccinating IV according to Table 4. In this study, the naïve spleen cells were pulsed with  $\beta$ -gal, AH1, or AH1-A5 (SPSYAYHQF (SEQ ID NO:9)). The  $\beta$ -gal pulsed cells were labeled with low CFSE, the AH1 and AH1-A5 with high CFSE. Three mice of each set were injected at day 6 with  $\beta$ -gal and AH-1 pulsed cells as above. The remaining three of each set were injected at day 6 with  $\beta$ -gal and AH1-A5 pulsed cells. The results are shown in Table 4 and Figure 1C.

Table 4. *In vivo* cytotoxicity (% kill of target cells relative to a non vaccinated control sample) of Balb/c mice vaccinated as indicated.

Immunization	# of mice	Vaccination dose	Target	% kill
HBSS	3	100 $\mu$ L	AH1	0
$\Delta actA \Delta inlB$	3	$1 \times 10^7$ in 100 $\mu$ L	AH1	0.7
$\Delta actA \Delta inlB$ AH1-A5	3	$1 \times 10^7$ in 100 $\mu$ L	AH1	31.8
HBSS	3	100 $\mu$ L	AH1-A5	0
$\Delta actA \Delta inlB$	3	$1 \times 10^7$ in 100 $\mu$ L	AH1-A5	5.7
$\Delta actA \Delta inlB$ AH1-A5	3	$1 \times 10^7$ in 100 $\mu$ L	AH1-A5	94.9

Example 4. Therapeutic vaccination with *Listeria monocytogenes*  $\Delta actA \Delta inlB$  double mutant

[0242] Using Balb/c mice, CT26 tumor cells (ATCC CRL-2639) were injected into the mice ( $2 \times 10^5$  in 100  $\mu$ L IV in HBSS) to establish lung metastases. The CT26 cells are a murine colon adenocarcinoma that express the MMTV gp70 epitope AH1. (The cells were further modified to express a human tumor antigen, although this characteristic is not relevant to the data presented here.) Several studies were done to assess the use of *Listeria monocytogenes*  $\Delta actA \Delta inlB$  as an effective therapeutic vaccine strain. In one study, *Listeria monocytogenes* strains  $\Delta actA$ ,  $\Delta actA$  modified to express AH1-A5, , and  $\Delta actA \Delta inlB$  modified to express AH1-A5 were used for vaccinating groups of thirteen mice. All strains were grown in BHI medium (Brain Heart Infusion, Fisher Scientific) at 37 °C at 300 rpm and stored frozen prior to use. The frozen stock of each strain was diluted into HBSS and the mice were vaccinated intravenously with  $1 \times 10^7$  CFU in 100  $\mu$ L for each strain four days after the tumor implant, as well as with 100  $\mu$ L HBSS control. Twenty days post tumor implant, three mice per group were sacrificed and the lungs harvested (shown in Figure 2A).

[0243] The remaining ten mice per group were monitored for survival (data not shown). Additional studies were done on groups of ten mice (survival only, lungs were not harvested from any of the mice) using  $\Delta actA$  AH1-A5, and  $\Delta actA \Delta inlB$  AH1-A5 as well as L461T expressing OVA as an irrelevant antigen control in one study and  $\Delta actA$  expressing



FluHA as an irrelevant antigen in another study. The survival results for these studies are shown in Figures 2B and 2C, respectively. The AH1 antigen is endogenous to the mice, such that any immunization effect would be breaking immune tolerance in the mice. The results indicate that the  $\Delta actA \Delta inlB$  mutant is an effective vaccine that breaks tolerance in this model and significantly enhances survival in tumor bearing mice.

Example 5. Immunogenicity of various strains of *Listeria monocytogenes* following intramuscular administration.

[0244] C57BL/6 mice (3 per group) were injected IM with 100  $\mu$ L HBSS containing 0.1 LD<sub>50</sub> of *Listeria monocytogenes* strains indicated in Table 5. All strains were grown in BHI medium (Brain Heart Infusion, Fisher Scientific) at 37 °C at 300 rpm and stored frozen prior to use. The mice were sacrificed 7 days after vaccination and the spleens were harvested and assessed by Intracellular Cytokine Staining (ICS).

[0245] For ICS, spleen cells from vaccinated and control groups of mice were incubated with SL8 OVA<sub>257-264</sub> peptide (SL8 OVA antigen, SIINFEKL (SEQ ID NO:21), Invitrogen, San Diego, CA) which stimulates OVA specific CD8<sup>+</sup> cells, LLO<sub>190</sub> (NEKYAQAYPNVS (SEQ ID NO:22), Invitrogen) an MHC class II epitope for listeriolysin O (*Listeria* antigen), or LLO<sub>296</sub> (VAYGRQVYL (SEQ ID NO:23), Invitrogen), an MHC class I epitope for listeriolysin O, for 5 hours in the presence of Brefeldin A (Pharmingen). The Brefeldin A inhibits secretion of the cytokines produced upon stimulation of the T cells. Spleen cells incubated with an irrelevant MHC class I peptide were used as controls. PMA (phorbol-12-myristate-13-acetate, Sigma) 20 ng/mL and ionomycin (Sigma) 2  $\mu$ g/mL stimulated spleen cells were used as a positive control for IFN- $\gamma$  and TNF- $\alpha$  intracellular cytokine staining. For detection of cytoplasmic cytokine expression, cells were stained with FITC-anti-CD4 mAb (RM 4-5) and PerCP-anti-CD8 mAb (53-6.7), fixed and permeabilized with Cytofix/CytoPerm solution (Pharmingen), and stained with PE-conjugated anti-TNF- $\alpha$  mAb (MP6-XT22) and APC-conjugated anti-IFN- $\gamma$  mAb (XMG1.2) for 30 minutes on ice. The percentage of cells expressing intracellular IFN- $\gamma$  and/or TNF- $\alpha$  was determined by flow cytometry (FACScalibur, Becton Dickinson, Mountain View, CA) and data analyzed using CELLQuest software (Becton Dickinson Immunocytometry System). As the fluorescent labels on the various antibodies can all be distinguished by the FACScalibur, the appropriate cells were identified by gating for those CD8<sup>+</sup> and CD4<sup>+</sup> that were stained with either or

both of the anti-IFN- $\gamma$  or anti-TNF- $\alpha$ . The results are indicated in Figures 3A-F. The  $\Delta actA \Delta inlB$  strain is one of the more effective strains at eliciting an OVA specific immune response.

Table 5. Vaccination of C57BL/6 mice with various strains of *Listeria monocytogenes*.

Vaccination strain	Description	Vaccination dose
DP-L4029	$\Delta actA$	$1 \times 10^7$
DP-L4017 OVA	L461T LLO mutant, expresses OVA	$7.5 \times 10^6$
DP-L4027 OVA	$\Delta hI$ (LLO) mutant, expresses OVA	$1 \times 10^8$
DP-L4029 OVA	$\Delta actA$ mutant, expresses OVA	$1 \times 10^7$
DP-L4038 OVA	$\Delta actA$ L461T double mutant, expresses OVA	$2 \times 10^7$
DP-L4042 OVA	LLO $\Delta 26$ (PEST) mutant, expresses OVA	$5 \times 10^7$
DP-L4056 OVA	Wild type, expresses OVA	$5 \times 10^4$
DP-L4097 OVA	S44A LLO mutant, expresses OVA	$1 \times 10^7$
DP-L 4364 OVA	$\Delta plI$ mutant, expresses OVA	$2 \times 10^7$
DP-L4384 OVA	LLO S44A/L461T double mutant, expresses OVA	$5 \times 10^7$
DP-L4404 OVA	$\Delta inlA \Delta inlB$ double mutant, expresses OVA	$5 \times 10^4$
DP-L4405 OVA	$\Delta inlA$ mutant, expresses OVA	$5 \times 10^4$
DP-L 4406 OVA	$\Delta inlB$ mutant, expresses OVA	$1 \times 10^5$
P60-LLO OVA	$\Delta P60$ mutant, expresses OVA	$1 \times 10^6$
DP-L4029 $lplA^-$ OVA	$\Delta actA \Delta lplA$ double mutant, expresses OVA	$2 \times 10^8$
DP-L4029 $\Delta inlB$ OVA	$\Delta actA \Delta inlB$ double mutant, expresses OVA	$1 \times 10^8$
MACKuvr <sup>-</sup> LLO OVA/AH1	$\Delta uvr$ mutant, expresses OVA/AH1	$2 \times 10^5$

Example 6. Assessment of OVA-specific immunity induced by *Listeria monocytogenes* strains in C57BL/6 mice.

[0246] C57BL/6 mice (3 per group) were injected IV with 200  $\mu$ L HBSS containing 0.1 LD<sub>50</sub> of the strains indicated in Table 6. The  $\Delta inlB$  strain was injected at too high of a

dose and those mice did not survive 7 days. The mice were sacrificed 7 days after vaccination and the spleens were harvested and antigen-specific T cell responses to the heterologous antigen ovalbumin (OVA) and to *Listeria* antigen, LLO, were assessed by ICS per Example 5. In addition to stimulating spleen cells of vaccinated and control mice with the T cell epitopes for OVA, SL8 (OVA257-264), and for LLO (LLO190-201, LLO296-304), the cells were stimulated for 5 hours with murine thymoma derived from C57BL/6 mice (EL-4) and EL-4 cells stably transfected with a plasmid encoding ovalbumin (EG-7). The stimulator cells were used either live or following inactivation with 150  $\mu$ M of psoralen S-59 and 3 J/cm<sup>2</sup> UVA light (FX 1019 irradiation device, Baxter Fenwal, Round Lake, IL). The inactivation with S-59 is referred to as photochemical treatment (PCT) and results in complete inactivation of the cells. The results, excluding the LLO stimulated samples, for IFN- $\gamma$  are shown in Figure 4. Comparable stimulation of spleen cells of vaccinated mice was observed when either the optimal T cell epitope SL8 or whole tumor cells, live or inactivated, were used for the 5 hour stimulation. The stimulation with whole cells implies that the OVA-specific T cells recognize endogeneous levels of OVA in the context of tumor cells. The  $\Delta actA \Delta inlB$  strain results in a relatively strong OVA specific response for stimulation with peptide as well as whole cells.

Table 6. Vaccination of C57BL/6 mice with various strains of *Listeria monocytogenes*.

Vaccination strain	Description	Vaccination dose (CFU)
HBSS	Control	100 $\mu$ L
DP-L4029 $\Delta$ inlB	$\Delta$ actA $\Delta$ inlB double mutant	$1 \times 10^8$
DP-L4056 OVA	Wild type	$5 \times 10^4$
DP-L4017 OVA	L461T LLO mutant	$7.5 \times 10^6$
DP-L4029 OVA	$\Delta$ actA	$1 \times 10^7$
DP-L 4364 OVA	<i>lplA</i> <sup>-</sup>	$2 \times 10^7$
DP-L 4406 OVA	$\Delta$ inlB	$1 \times 10^6$
DP-L4038 OVA	$\Delta$ actA L461T double mutant	$2 \times 10^7$
DP-L4029 <i>lplA</i> <sup>-</sup> OVA	$\Delta$ actA $\Delta$ <i>lplA</i> double mutant	$2 \times 10^8$
DP-L4017 <i>lplA</i> <sup>-</sup> OVA	<i>lplA</i> <sup>-</sup> L461T double mutant	$1 \times 10^7$
DP-L4029 $\Delta$ inlB OVA	$\Delta$ actA $\Delta$ inlB double mutant	$1 \times 10^8$

[0247] Another study was done to look at a dose response using *Listeria monocytogenes* wild type,  $\Delta$ actA and  $\Delta$ actA $\Delta$ inlB strains modified to express OVA. C57BL/6 mice (3 per group) were injected IV with 200  $\mu$ L HBSS as follows; wild type at  $5 \times 10^4$ ,  $5 \times 10^3$ ,  $5 \times 10^2$ ,  $5 \times 10^1$ ,  $\Delta$ actA at  $1 \times 10^7$ ,  $1 \times 10^6$ ,  $1 \times 10^5$ ,  $5 \times 10^4$ ,  $1 \times 10^4$ , and  $\Delta$ actA $\Delta$ inlB at  $1 \times 10^8$ ,  $1 \times 10^7$ ,  $1 \times 10^6$ ,  $1 \times 10^5$ ,  $5 \times 10^4$ . The mice were sacrificed 7 days after vaccination and the spleens were harvested and assessed by ICS, stimulating with SL8, LLO<sub>190</sub> and LLO<sub>296</sub> peptides. The results are shown in Figure 5.

Example 7. Immunogenicity of *Listeria monocytogenes*  $\Delta$ actA $\Delta$ inlB double mutant expressing LLO-OVA administered via different routes in mice.

[0248] Balb/c mice were injected with *Listeria monocytogenes*  $\Delta$ actA (DP-L4029) or *Listeria monocytogenes*  $\Delta$ actA $\Delta$ inlB double mutant, where both mutants were engineered to express OVA antigen. Mice (three per group) were injected with  $1 \times 10^7$  CFU of  $\Delta$ actA or  $1 \times 10^8$  CFU of  $\Delta$ actA $\Delta$ inlB in HBSS either 200  $\mu$ L IV (intravenous), 100  $\mu$ L SC (subcutaneous), 100  $\mu$ L IM (intramuscular, 50  $\mu$ L per quadriceps of each leg), 50  $\mu$ L IM (25  $\mu$ L per tibialis of each leg), 50  $\mu$ L ID (intradermal), or 200  $\mu$ L IP (intraperitoneal). Seven days post vaccination, the spleens were removed and assessed by Intracellular Cytokine

Staining (ICS) per Example 5 (SL8 only, IFN- $\gamma$  only). Figure 6 shows the % of CD-8+ OVA specific T-cells in the spleen, indicating that the *actA/inlB* mutant gives a greater response than  $\Delta actA$  by several routes of administration, with IV, IP, and IM routes showing the highest responses.

Example 8. In vivo growth kinetics of *Listeria monocytogenes*  $\Delta actA\Delta inlB$  mutant in naïve immuno-competent C57BL/6 mice.

[0249] Although attenuated strains of *Listeria* can be administered at higher doses compared to wild type, it is important for the development of a safe vaccine that the infection can be cleared rapidly, without damaging the primary organs of infection, i.e. liver or spleen.

[0250] C57BL/6 mice were injected with either DP-L4056 (wild type) DP-L4029 ( $\Delta actA$ ), DP-L 4406 ( $\Delta inlB$ ) or  $\Delta actA\Delta inlB$  strains of *Listeria monocytogenes*. Injections were 100  $\mu$ L IV in HBSS at the levels indicated in Table 7, 35 mice per group including HBSS control group. All strains were grown in BHI medium (Brain Heart Infusion, Fisher Scientific) at 37 °C at 300 rpm and stored frozen prior to use. Three mice per group were sacrificed at the timepoints indicated in Table 7, and blood, spleen and liver were removed for analysis. The liver and spleens were homogenized in 5 mL of double distilled water with 0.05% Triton X-100 and the number of viable *Listeria* were determined by plating serial dilutions on BHI/streptomycin plates. The liver and spleens were fixed in 10% buffered formalin for 2 mice per group. The results for CFU per liver and spleen are indicated in Figures 7A and 8A. The experiments were also repeated at the strain concentrations shown in Figures 7B and 8B.

[0251] Infection of mice with wild type *Listeria* resolved within 8 to 11 days post administration. The number of wild type *Listeria* steadily increased significantly over the time period of 4 days and decreased to the minimum level of detection in spleen and liver by day 11. Interestingly, the  $\Delta inlB$  mutant demonstrated a similar kinetic in spleen as well as the liver, with induction of sterile immunity at day 11. In contrast, the number of  $\Delta actA$  mutant only increased over the first 24 hrs 10-fold in the liver, but not in the spleen, and eventually decreased following day 4 post infection. The  $\Delta actA\Delta inlB$  double mutant, although administered at the highest dose, was eliminated very quickly in the liver as compared to the other three strains and sterile immunity was induced by day 4. The accelerated clearance of

the bacteria stands in contrast with its ability to induce potent protective as well as antigen-specific immunity in therapeutic tumor model.

Table 8. Dosing and sampling schedule for *in vivo* growth kinetic study of attenuated *Listeria monocytogenes*.

Strain	Dose	Take down time post injection
HBSS	100 $\mu$ L	2hrs, days 1, 2, 3, 4, 7, and 10
Wild type	$5 \times 10^4$	2hrs, days 1, 2, 3, 4, 7, and 10
$\Delta actA$	$1 \times 10^7$	2hrs, days 1, 2, 3, 4, 7, and 10
$\Delta inlB$	$5 \times 10^4$	2hrs, days 1, 2, 3, 4, 7, and 10
$\Delta actA \Delta inlB$	$1 \times 10^7$	2hrs, days 1, 2, 3, 4, 7, and 10

Example 9. *In vitro* infection of non-phagocytic vs phagocytic cells with various strains of *Listeria monocytogenes*.

[0252] *Listeria monocytogenes* wild type,  $\Delta actA$ ,  $\Delta inlB$  and  $\Delta actA \Delta inlB$  strains were incubated (37 °C with 5% CO<sub>2</sub>) with human monocyte cell line THP-1 (ATCC #TIB-202), primary human monocytes, human hepatocyte cell line HepG2 (from Drew Pardoll, Johns Hopkins University; also available as ATCC # HB8065), or primary human hepatocytes (*In vitro* Technologies, Baltimore, MD). Primary human monocytes were prepared from whole blood using a Ficoll gradient to purify lymphocytes, then monocytes were isolated using magnetic beads conjugated to monocyte specific antibody (Miltenyi Biotec). THP-1 and human monocytes were incubated in RPMI media supplemented with 10% heat-inactivated fetal bovine serum (FBS), 23.8 mM sodium bicarbonate, 1x non-essential amino acids, 2 mM L-glutamine, 10 mM HEPES buffer, and 1 mM sodium pyruvate. The *Listeria* strains were added at  $5 \times 10^5$  CFU to  $5 \times 10^5$  THP-1 cells and  $3.5 \times 10^7$  CFU to  $3.5 \times 10^5$  monocytes. HepG2 cells were incubated in Minimal Essential Media Eagle supplemented with 20% heat-inactivated fetal calf serum, 2 mM L-glutamine, and 1x non-essential amino acids. The *Listeria* strains were added at  $1 \times 10^6$  CFU to  $1 \times 10^5$  HepG2 cells. Primary human hepatocytes were incubated in Hepatocyte Growth Incubation Media (*In vitro* Technologies) prior to adding *Listeria* and incubated in DMEM supplemented with 10% FBS, 2mM L-glutamine and 1x non-essential amino acids after adding the *Listeria*. The *Listeria* strains were added at  $3.5 \times 10^6$  CFU to  $3.5 \times 10^5$  hepatocytes. After incubation for one hour, the cells

were washed with complete media containing gentamicin (50 µg/mL) in order to kill any extracellular bacteria. The cells were then lysed with 225 µL sterile water, then 25 mL of 10x PBS was added. The resulting solution was plated on BHI with serial dilutions to assess the bacterial titer from each sample. The number of *Listeria* infecting the cells was divided by the *Listeria* added to the cells to determine the infectivity of the strain, normalized to the infectivity of the wild type strain.

[0253] The results are shown in Figure 9. As shown in Figure 9, all strains are able to infect THP-1 cells and human monocytes at a similar rate, demonstrating that the absence of ActA or InlB does not affect the infection of phagocytic cells. However, the infection of hepatocytes was significantly decreased for *Listeria* strains lacking InlB. There is approximately a 60% reduced infection of human hepatocytes and a 80% reduction in HepG2 cells when infecting with either of the InlB null mutant strains,  $\Delta inlB$  or  $\Delta actA\Delta inlB$ . These studies demonstrate that the deletion of InlB protein selects for uptake by phagocytic cells by preventing the infection of cultured and primary hepatocytes.

Example 10. *In vitro* infection of non-phagocytic vs phagocytic cells with opsonized *Listeria monocytogenes*.

[0254] Wild-type *Listeria* was pre-incubated with high titer *Listeria*-specific mouse serum from mice infected iv with  $\Delta actA$  *Listeria* mutant (1:20 dilution) or HBSS as a control for 1 hour in ice. The phagocytic dendritic cell-like cell line (DC 2.4) and the non-phagocytic colon epithelial cell line (Caco-2) were infected at MOIs of 1 and 10, respectively, for 1 hour at 37°C. The cells were washed three times to remove extracellular bacteria. Cells were cultured for an additional 2 hours in the presence of 50 mg/ml gentamicin to kill remaining extracellular bacteria. To determine the infectivity of the cell lines, cells were lysed with dH<sub>2</sub>O containing 0.01% Triton X-100. The number of viable *Listeria* was determined by plating serial dilutions onto BHI agar plates.

[0255] As shown in Figure 10, *Listeria*  $\Delta actA$  incubated with high-titer immune serum from vaccinated mice have a reduced ability to infect the non-phagocytic cell line Caco-2, but not of the phagocytic dendritic cell line DC2.4. The decreased infection of non-phagocytic cells by opsonized *Listeria* is comparable to the attenuated *Listeria* strain that is deleted for actA and inlB (Figure 9). Without wishing to be bound by theory, the use of *Listeria*-specific antibodies (monoclonal antibody targeting internalins, or polyclonal Abs)

may block the receptors on the surface of the *Listeria ΔactA* bacterium that enable the infection of non-phagocytic cells *in vivo*.

Example 11. Exemplary S-59 psoralen UVA treatment of *Listeria*

[0256] An *ΔactAΔuvrAB* mutant strain of *Listeria* (DP-L4029 *uvrAB*) was modified to express the OVA antigen. This strain and DP-L4029 modified to express OVA were treated with the psoralen S-59 at various concentrations. The *Listeria* strains were grown overnight at 37 °C and a 2 mL aliquot was diluted into 100 mL of BHI and grown approximately 4 hours at 37 °C to an OD600 of 0.5 (approximately  $1 \times 10^9$  CFU/mL). A 5 mL aliquot of each *Listeria* strain was added to a 15 mL tube and centrifuged for 20 minutes at 2300 x g, the supernatant removed, and the bacteria resuspended in 5 mL of PBS resulting in approximately  $1 \times 10^9$  CFU/mL. For the *uvrAB* mutant strain, 3 mM S-59 stock was diluted 33.3 μL to 10 mL PBS to give a 10 μM solution, and appropriate aliquots of this was added to the *Listeria* to final concentrations of 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 nM, while for the DP-L4029, S-59 was added to final concentrations of 100, 200, 400, 800, and 1000 nM in a final volume of 5 mL. These were transferred to a 6 well culture plate and irradiated for a dose of 0.5 J/cm<sup>2</sup> (FX1019 UVA device). The samples were transferred to 15 mL tubes, 5 mL PBS was added, and they were centrifuged for 20 minutes at 2300 x g to wash out unreacted psoralen. The supernatant was removed and the bacteria resuspended in 5 mL PBS and transferred to new 6 well plates. These were irradiated at a UVA dose of 5.5 J/cm<sup>2</sup> in order to convert psoralen monoadducts to crosslinks. A sample of each *Listeria* strain was also heat killed by treating at 72 °C for 3 hours.

[0257] The antigen presentation of the bacterial samples was assessed using a murine DC 2.4 cell line (dendritic cell line from the Dana Farber Cancer Institute, see Shen et al., J Immunol 158(6):2723-30 (1997)) and a B3Z T cell hybridoma (obtained from Dr. Shastri, University of California, Berkeley). The B3Z is a lacZ inducible CD8+ T cell hybridoma that expresses a β-galactosidase gene upon recognition of OVA antigen in context of MHC class I molecules. The metabolism of CPRG (chlorophenolred-β-D-galactopyranoside, Calbiochem, La Jolla, CA), a substrate for the β-galactosidase, was used to assess the level of β-galactosidase produced, which is directly correlated to the amount of OVA antigen presented by the DC 2.4 cells. The DC 2.4 cells and the B3Z T cell hybrid were maintained in RPMI 1640 culture medium (RPMI, Invitrogen) with 10% FBS (fetal bovine serum, HyClone ).



The DC 2.4 cells were transferred in 200  $\mu\text{L}$  aliquots to the wells of a 96 well culture plate ( $1 \times 10^5$  DC 2.4 per well). The bacterial samples were serially diluted 50  $\mu\text{L}$  stock to 450  $\mu\text{L}$  PBS down to  $1 \times 10^5$  CFU/mL (S-59 treated samples are CFU equivalents, i.e. it is the number of colony forming units prior to S-59 treatment). A 20  $\mu\text{L}$  aliquot of each dilution is transferred to a well containing the DC 2.4 cells to give approximately  $1 \times 10^4$ ,  $1 \times 10^5$ ,  $1 \times 10^6$ ,  $1 \times 10^7$ , or  $1 \times 10^8$  CFU/mL. In addition, a 20  $\mu\text{L}$  aliquot of PBS only was added as a negative control. The samples were incubated for 1 hour at  $37^\circ\text{C}$  in 5%  $\text{CO}_2$ . The plate was washed three times with PBS to remove extracellular bacteria. A 200  $\mu\text{L}$  aliquot of B3Z T cells ( $1 \times 10^5$  cell) and 100  $\mu\text{g/mL}$  Gentamycin (Sigma) was added to each well. As a positive control, 100 nM SL8 OVA<sub>257-264</sub> peptide (SL8 OVA antigen, SIINFEKL (SEQ ID NO:21), Invitrogen, San Diego, CA) was added to a well containing  $1 \times 10^5$  each of the DC 2.4 and B3Z cells. The samples were incubated overnight at  $37^\circ\text{C}$  in 5%  $\text{CO}_2$ . The plate was centrifuged for 3 minutes at  $400 \times g$  and each well washed with 250  $\mu\text{L}$  of PBS. A 100  $\mu\text{L}$  aliquot of PBS containing 100  $\mu\text{M}$  2-mercaptoethanol, 9 mM  $\text{MgCl}_2$ , 0.125% Igepal CA-630 ((Octaphenoxy)polyethoxyethanol, Sigma), and 0.15 mM CPRG was added to each well. The samples were incubated at  $37^\circ\text{C}$  for at least 4 hours. The absorbance was measured at 595 nm with a reference measurement at 655 nm using a plate reader.

[0258] The results for the S-59 treated samples are found in Table 8A and Figures 11A and 11B (antigen presentation at 1 *Listeria* per DC 2.4 cell, calculated without subtracting background levels). The results for both heat killed strains showed a titer below the limit of detection (complete inactivation) and the heat killed bacteria did not present OVA antigen in the B3Z assay. The results indicate that the *uvrAB* mutant shows very strong antigen presentation even with attenuation of proliferation to the limit of detection where the non *uvrAB* mutant strain shows a greater reduction in the antigen presentation as a function of attenuation of proliferation (to approximately background levels with essentially complete inactivation). This demonstrates that the *uvrAB* mutant retains MHC class I presentation in the context of psoralen attenuated *Listeria* and should provide a vaccine with an effective immune response and significantly increased level of safety.

Table 8A Log attenuation and OVA antigen presentation of *Listeria* strains UVA treated with varying concentrations of psoralen S-59.

[S-59] nM	Log attenuation		% OVA antigen presented*	
	DP-L4029- OVA	DP-L4029 <i>uvrAB</i> -OVA	DP-L4029- OVA	DP-L4029 <i>uvrAB</i> -OVA
10		2.47		84
20		3.93		84
30		5.28		76
40		6.44		76
50		6.92		68
60		>7.62		84
70		>7.62		84
80		>7.62		88
90		>7.62		92
100	3.85	>7.62	50	92
200	5.48		47	
400	6.78		19	
800	>7.78		13	
1000	>7.78		13	

\* As percent of untreated, measured at 1 *Listeria* per DC 2.4 cell.

[0259] Another study was done using the same strains. In this study the *Listeria* were grown in BHI at 37 °C overnight. These were diluted 1:50 into BHI and grown at 37 °C at 300 rpm to an OD<sub>600</sub> of 0.5, at which point 50 mL of solution was transferred to a clean flask and S-59 was added to a to the levels indicated in Table 12B. These samples were incubated at 37 °C at 300 rpm for approximately 1 hour (OD<sub>600</sub> approximately 1.0, approximately 1 x 10<sup>9</sup>/mL). A 1 mL aliquot was removed to assess the titer and the remaining was transferred to a 150 mm Petri dish and irradiated at a dose of 6 J/cm<sup>2</sup> (FX1019). The titer post irradiation was determined for each sample and the OVA antigen presentation was assessed as above. The results are found in Table 8B and Figures 11C and 11D (antigen presentation at 10 *Listeria* per DC 2.4 cell, calculated without subtracting background levels). The results indicate that for the parent strain, the antigen presentation is at background levels where there is essentially complete inactivation whereas for the *uvrAB*

mutant, there is an approximately 10-fold range of S-59 concentration over which there is essentially complete inactivation along with adequate antigen presentation.

Table 8B Log attenuation and OVA antigen presentation of *Listeria* strains UVA treated with varying concentrations of psoralen S-59 present during growth of the bacteria.

[S-59] μM	Log attenuation		% OVA antigen presented*	
	DP-L4029- OVA	DP-L4029 <i>uvrAB</i> -OVA	DP-L4029- OVA	DP-L4029 <i>uvrAB</i> -OVA
0.025		3.64		91
0.05		5.70		86
0.1		>8.10		87
0.2		>8.10		86
0.25	2.00		50	
0.4		>8.10		74
0.5	5.28		31	
0.8		>8.10		50
1.0	7.57		14	
1.6		>8.10		35
2.0	>8.38		11	
3.2		>8.10		16
4.0	>8.38		10	
6.4		>8.10		11
8.0	>8.38		10	
16.0	>8.38		11	

\* As percent of untreated, measured at 10 *Listeria* per DC 2.4 cell.

**Example 12. Effectiveness of *Listeria* mutants in stimulating antigen-specific responses in the presence of pre-existing immunity and/or antibodies**

[0260] Pre-existing anti-*Listeria* immunity was induced by infecting C57BL/6 mice IP with 0.1 LD<sub>50</sub> of wild-type *Listeria* given once or three times (10 days apart). Mice with *Listeria* immunity (1 or 3 vx) and naïve mice were vaccinated ip 32 days post last *Listeria* exposure with 0.1 LD<sub>50</sub> of the indicated *Listeria* strain. Seven days later spleens were

harvested and the frequency of OVA-specific CD8+ T cells was determined by intracellular cytokine staining for IFN-g. The results are shown in Figure 12A. Priming of OVA-specific CD8+ T-cell responses were observed in mice with a level of pre-existing immunity that protects against a lethal challenge of wild type *Listeria*.

[0261] Pre-existing anti-*Listeria* immunity was induced in all C57BL/6 mice by infecting intraperitoneally with 0.1 LD50 of wild-type *Listeria*. Mice were vaccinated ip 70 days later with 0.1 LD50 of the indicated *Listeria* strain. After 21 days, mice were implanted subcutaneously with 2e5 B16-OVA tumor cells, and tumors were measured twice weekly. The results are shown in Figure 12B. Tumor studies demonstrated that the OVA-specific immune response mounted in the presence of anti-*Listeria* immunity can effectively protect against B16-OVA tumor challenge.

[0262] High titer immune serum was generated by infecting C57BL/6 mice intravenously four times with 0.1 LD50 of the indicated strain. Immune and non-immune serum was harvested and titer determined by *Listeria*-specific ELISA. Naïve C57BL/6 mice were injected iv with 200 ul of saline, serum (immune or non-immune), or rabbit polyclonal anti-*Listeria* antibody on Day -1 and 1. Mice were vaccinated iv with 0.1 LD50 of  $\Delta actA$ -OVA *Listeria* on Day 0. Spleens were harvested and the frequency of OVA-specific CD8+ T cells was determined by intracellular cytokine staining for IFN-g. The results are shown in Figure 12C. The results show that passive transfer of *Listeria*-specific antibody to naïve mice did not reduce priming of a primary OVA-specific cellular immune response in treated mice.

[0263] All publications, patents, patent applications, and accession numbers (including both polynucleotide and polypeptide sequences) cited herein are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent or patent application were specifically and individually indicated to be so incorporated by reference.

## CLAIMS

What we claim is:

1. An isolated *Listeria* bacterium which is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-Listerial antigen.
2. The attenuated *Listeria* bacterium of claim 1, which is further attenuated for cell-to-cell spread.
3. The attenuated *Listeria* bacterium of claim 2, which comprises at least one mutation in one or more gene selected from the group consisting of *actA*, *lplA*, *plcA*, *plcB*, *mpl* and *hly*.
4. The attenuated *Listeria* bacterium of claim 3, which comprises a mutation in *actA*.
5. The attenuated *Listeria* bacterium of claim 2, wherein nucleic acid of the bacterium has been modified by reaction with a nucleic acid targeting compound so that proliferation of the bacterium is attenuated.
6. The attenuated *Listeria* bacterium of claim 5, wherein nucleic acid of the bacterium has been modified by contact with a psoralen activated by UVA irradiation.
7. The attenuated *Listeria* bacterium of claim 1, which is defective with respect to one or more internalins.
8. The attenuated *Listeria* bacterium of claim 7, which is defective with respect to internalin B.
9. The attenuated *Listeria* bacterium of claim 8, which comprises a mutation in the *inlB* gene.

10. The attenuated *Listeria* bacterium of claim 8, which is further attenuated for cell-to-cell spread.
11. The attenuated *Listeria* bacterium of claim 10, which is defective with respect to ActA.
12. The attenuated *Listeria* bacterium of claim 11, which comprises at least one mutation in both *actA* and *inlB*.
13. The attenuated *Listeria* bacterium of claim 1, which belongs to the species *Listeria monocytogenes*.
14. The attenuated *Listeria* bacterium of claim 1, wherein the antigen is a tumor-associated antigen or derived from a tumor-associated antigen.
15. The attenuated *Listeria* bacterium of claim 14, wherein the antigen is a tumor associated antigen or derived from a tumor associated antigen selected from the group consisting of mesothelin, sp17, PAGE-4, gp-100, PSMA, K-ras, TARP, proteinase 3, WT-1, NY-ESO-1, CEA, Her-2, and SPAS-1.
16. The attenuated *Listeria* bacterium of claim 1, wherein the antigen is an infectious disease antigen or is derived from an infectious disease antigen.
17. The immunogenic composition comprising the attenuated *Listeria* bacterium of claim 1.
18. A vaccine comprising (a) the attenuated *Listeria* bacterium of claim 1, and (b) a pharmaceutically acceptable carrier or adjuvant.
19. A method of inducing an immune response in a host to a non-Listerial antigen comprising administering to the host an effective amount of a composition comprising the attenuated *Listeria* bacterium of claim 1.

20. A method of preventing or treating a disease in a host, comprising administering to the host an effective amount of a composition comprising the attenuated *Listeria* bacterium of claim 1.
21. A professional antigen-presenting cell comprising the attenuated *Listeria* strain of claim 1.
22. An isolated *Listeria* bacterium which is attenuated both for entry into non-phagocytic cells and for cell-to-cell spread.
23. The attenuated *Listeria* bacterium of claim 22, which comprises at least one mutation in one or more gene selected from the group consisting of *actA*, *lplA*, *plcA*, *plcB*, *mpl* and *hly*.
24. The attenuated *Listeria* bacterium of claim 23, which comprises a mutation in *actA*.
25. The attenuated *Listeria* bacterium of claim 22, wherein nucleic acid of the bacterium has been modified by reaction with a nucleic acid targeting compound so that proliferation of the bacterium is attenuated.
26. The attenuated *Listeria* bacterium of claim 25, wherein nucleic acid of the bacterium has been modified by contact with a psoralen activated by UVA irradiation.
27. The attenuated *Listeria* bacterium of claim 22, wherein the attenuated *Listeria* bacterium is defective with respect to one or more internalins.
28. The attenuated *Listeria* bacterium of claim 27, which is defective with respect to internalin B.
29. The attenuated *Listeria* bacterium of claim 28, which comprises at least one mutation in the *inlB* gene.

30. The attenuated *Listeria* bacterium of claim 28, which is defective with respect to ActA.
31. The attenuated *Listeria* bacterium of claim 30, wherein the attenuated *Listeria* bacterium comprises at least one mutation in both *actA* and *inlB*.
32. The attenuated *Listeria* bacterium of claim 22, which belongs to the species *Listeria monocytogenes*.
33. The attenuated *Listeria* bacterium of claim 22, which comprises a nucleic acid molecule encoding a non-Listerial antigen.
34. The attenuated *Listeria* bacterium of claim 33, wherein the non-Listerial antigen is a tumor-associated antigen or derived from a tumor associated antigen.
35. The attenuated *Listeria* bacterium of claim 34, wherein the antigen is a tumor associated antigen or derived from a tumor associated antigen selected from the group consisting of mesothelin, sp17, PAGE-4, gp-100, PSMA, K-ras, TARP, proteinase 3, WT-1, NY-ESO-1, CEA, Her-2, and SPAS-1.
36. The attenuated *Listeria* bacterium of claim 33, wherein the non-Listerial antigen is an infectious disease antigen or is derived from an infectious disease antigen.
37. An immunogenic composition comprising the attenuated *Listeria* bacterium of claim 22.
38. A vaccine comprising (a) the attenuated *Listeria* bacterium of claim 22, and (b) a pharmaceutically acceptable carrier or an adjuvant.
39. A method of inducing an immune response in a host to an antigen comprising administering to the host an effective amount of a composition comprising the attenuated



*Listeria* bacterium of claim 22, wherein the attenuated *Listeria* bacterium comprises a nucleic acid encoding the antigen.

40. A method of preventing or treating a disease in a host, comprising administering to the host an effective amount of a composition comprising the attenuated *Listeria* bacterium of claim 22.

41. A professional antigen-presenting cell comprising the attenuated *Listeria* bacterium of claim 22.

42. A strain selected from the group consisting of a *Listeria monocytogenes*  $\Delta actA \Delta inlB$  strain deposited with the American Type Culture Collection (ATCC) and identified by accession number PTA-5562, or a mutant of the deposited strain which is defective both with respect to internalin B and ActA.

43. The strain of claim 42, which is the *Listeria monocytogenes* strain deposited with the American Type Culture Collection (ATCC) and identified by accession number PTA-5562.

44. An immunogenic composition comprising the strain of claim 42.

45. A vaccine comprising (a) the strain of claim 42, and (b) a pharmaceutically acceptable carrier or adjuvant.

46. A method of inducing an immune response in a host to an antigen comprising administering to the host an effective amount of a composition comprising the strain of claim 42, wherein the strain comprises a nucleic acid molecule encoding the antigen.

47. A method of preventing or treating a disease in a host, comprising administering to the host an effective amount of a composition comprising the strain of claim 42.

48. A professional antigen-presenting cell comprising the strain of claim 42.

49. A vaccine comprising (a) a *Listeria* bacterium, wherein the attenuated *Listeria* bacterium is attenuated for entry into non-phagocytic cells, and (b) a pharmaceutically acceptable carrier or an adjuvant.
50. The vaccine of claim 49, wherein the attenuated *Listeria* bacterium is defective with respect to one or more internalins.
51. The vaccine of claim 49, wherein the attenuated *Listeria* bacterium is defective with respect to internalin B.
52. The vaccine of claim 49, wherein the attenuated *Listeria* bacterium comprises a mutation in the *inlB* gene.
53. The vaccine of claim 49, wherein the attenuated *Listeria* bacterium belongs to the species *Listeria monocytogenes*.
54. A method of preventing or treating a disease in a host, comprising administering to the host an effective amount of the vaccine of claim 49.
55. A method of inducing an immune response in a host to an antigen comprising administering to the host an effective amount of the vaccine of claim 49, wherein the attenuated *Listeria* bacterium comprises a nucleic acid molecule encoding the antigen.
56. A isolated professional antigen-presenting cell comprising a *Listeria* bacterium, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells.
57. A method of inducing an immune response in a host to an antigen comprising administering to the host an effective amount of the professional antigen-presenting cell of claim 56, wherein the attenuated *Listeria* bacterium comprises a nucleic acid encoding the antigen.

58. A method of preventing or treating a disease in a host, comprising administering to the host an effective amount of the professional antigen-presenting cell of claim 56.
59. A method of inducing MHC class I antigen presentation or MHC class II antigen presentation on an antigen-presenting cell *in vitro*, comprising contacting a *Listeria* bacterium with an antigen-presenting cell, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-Listerial antigen comprising an MHC class I epitope or an MHC class II epitope.
60. A method of inducing an immune response in a host to an antigen, comprising the following steps: (a) contacting a *Listeria* bacterium with an antigen-presenting cell from the host, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding the antigen; and (b) administering the antigen-presenting cell to the host.
61. A composition comprising a *Listeria* bacterium for medical use, wherein the *Listeria* bacterium is attenuated for entry into non-phagocytic cells and comprises a nucleic acid molecule encoding a non-Listerial antigen.
62. A composition comprising a *Listeria* bacterium for medical use, wherein the bacterium is attenuated for entry into non-phagocytic cells
63. The composition of claim 62, wherein the bacterium is further attenuated for cell-to-cell spread.
64. A kit comprising:
- (a) a composition comprising the *Listeria* bacterium of claim 1; and
  - (b) instructions for the use of the composition in the prevention or treatment of a disease in a host.
65. A kit comprising:
- (a) a composition comprising the *Listeria* bacterium of claim 22; and

(b) instructions for the use of the composition in the prevention or treatment of a disease in a host.

66. A kit comprising:

(a) a composition comprising a *Listeria* bacterium which is attenuated for entry into non-phagocytic cells; and

(b) instructions for the use of the composition in the prevention or treatment of a disease in a host.





Figure 1A







Figure 1C








Figure 2B




Figure 2C




Figure 3A




Figure 3B




Figure 3C

LLO 190- specific TNF $\alpha$  CD4+ T cells




Figure 3D




Figure 3E





Figure 3F





Vaccination

Figure 4




Figure 5




Figure 6




Figure 7A




Figure 7B




Figure 8A




Figure 8B




Figure 9






Figure 10




Figure 11A




Figure 11B




Figure 11C




Figure 11D




Figure 12A




Figure 12B




Figure 12C

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description on page <u>39</u> , line <u>5-7 (paragraph [0150])</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float:right">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution <p align="center">American Type Culture Collection (ATCC)</p>	
Address of depositary institution (including postal code and country) <p align="center">10801 University Blvd. Manassas, Virginia 20110-2209 United States of America</p>	
Date of deposit <p align="center">03 October 2003</p>	Accession Number <p align="center">PTA-5563</p>
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float:right">This information is continued on an additional sheet <input checked="" type="checkbox"/></span>	
<i>Listeria monocytogenes ΔactAΔuvrAB mutant</i>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")	


<p align="center"><b>For receiving Office use only</b></p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <input type="checkbox"/> This sheet was received with the international application       </div> <div style="border: 1px solid black; height: 40px; margin-bottom: 5px;">         Authorized officer       </div>	<p align="center"><b>For International Bureau use only</b></p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <input checked="" type="checkbox"/> This sheet was received by the International Bureau on:  <p align="center">07 JUNE 2004 (07.06.04)</p> </div> <div style="border: 1px solid black; height: 40px; margin-bottom: 5px;">         Authorized officer  </div>
---	---

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description on page <u>34</u> , line <u>8-10 (paragraph [0135])</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>	
Name of depositary institution <p align="center">American Type Culture Collection (ATCC)</p>	
Address of depositary institution (including postal code and country) <p>10801 University Blvd.          Manassas, Virginia 20110-2209          United States of America</p>	
Date of deposit <p align="center">03 October 2003</p>	Accession Number <p align="center">PTA-5562</p>
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input checked="" type="checkbox"/></span>	
<i>Listeria monocytogenes</i> $\Delta actA \Delta inlB$ double mutant	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p align="center"><b>For receiving Office use only</b></p> <p><input type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer</p>	<p align="center"><b>For International Bureau use only</b></p> <p><input checked="" type="checkbox"/> This sheet was received by the International Bureau on:</p> <p align="center">07 JUNE 2004 (07.06.04)</p> <p>Authorized officer</p> <p align="center"></p>
---	--



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS.
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**